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1.1 ALS; Pathogenesis 
Neurodegenerative disorders, such as amyotrophic lateral sclerosis (ALS), 
Parkinson's disease, and Alzheimer's disease represent a challenging class of disorders 
for both clinical and basic neuroscientists The pathogenesis of these neurological 
diseases remains largely unknown One of the most dramatic examples is amyotrophic 
lateral sclerosis (ALS), which was first described by Jean Martin Charcot 120 years ago 
ALS is primarily characterized by the selective loss of motor neurons in the cerebral 
cortex, the brain stem, and the spinal cord Motor neurons in ALS patients contain 
morphologically changed mitochondria and inclusion bodies Lewy-body-hke 
inclusions (filled with hyaline-like, ubiquitin positive amorphous material and a denser 
and eosinophilic core), Bunina bodies (small eosinophilic cytoplasmic bodies, 
consisting of amorphous material with sometimes fragments of neurofilament), 
spheroids (dilatations filled with disarrayed neurofilaments), ubiquinated inclusions 
(consisting of bundles of filaments), and neurofibrillary tangles (consisting of abnormal 
filaments) [Carpenter, 1968, Mirano et al, 1984, Hirano, 1996, Sasaki and Iwata, 
1996a] In addition, neuro-degenerative changes [Ince et al, 1996, Swash et al, 1988] 
have also been observed in large neurons localized in the substantia nigra and 
hippocampus [Takahashi et al, 1993] Besides the neurodegenerative appearance 
observed in these large neurons [Takahashi et al , 1993], also relatively small 
sympathetic intemeurons located in the ventral spinal gray of the spinal cord in a 
transgenic mouse model for amyotrophic lateral sclerosis are thought to be affected 
[Jaarsma et al , 1996] Altogether these observations imply that ALS in its final stages is 
not restricted to motor neurons Nevertheless, the earliest and most severe degenerative 
changes affect the lower and upper motor neurons, thereby resulting in muscle 
weakness, muscle atrophy, pathological reflexes, and spasticity [Williams and 
Windebank, 1991] The clinical picture is, however, not uniform some patients show 
first signs of spinal motor neuron death, such as muscle weakness in the limbs followed 
by limb impairment, whereas others develop predominantly bulbar signs, such as 
dysphagia and dysartna in the beginning [Williams and Windebank, 1991] ALS is a 
lethal disease of which the majonty of patients die from respiratory failure Without 
ventilatory assistance the mean survival is 2 to 3 years after diagnosis The incidence of 
ALS is 1 or 2 per 100,000 Although ALS is seen in all age groups, it is, essentially a 
disease of later life The average age at which the disease is diagnosed is 55 ALS 
affects more men than women in a 1 5 1 male/female ratio [Robberecht and Van Den 
Bosch, 1997] In ALS two forms can be distinguished a familial (fALS) and a sporadic 
(sALS) form Ten percent of all ALS patients suffer from the familial form and in 
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twenty percent of this group a mutation has been found in the Cu/Zn superoxide 
dismutase (SODI) gene on chromosome 21 [Rosen et al., 1993]. The group of sALS 
patients accounts for more than 90 % of all cases. The pathogenesis in this group is 
largely unknown, but there is a growing body of evidence that certain risk factors 
contribute to the development of sALS. A twin-study suggests that a genetic factor 
determines 35 to 85 % of the risk. A predisposition to ALS can result in the disease 
through triggering by exogenous factors [Graham et al., 1997]. Recently some factors 
that may increase the risk to develop sALS have been described: altered stoichiometry 
of cytoskeletal proteins in spinal motor neurons [Wong et al., 2000] and deletions of the 
survival motor neuron (SMN) gene 2 and/or neuronal apoptosis inhibitory protein 
(NAIP) genes [Kunst et al., 2000; Veldink et al., 2001]. 
1.2 ALS, a multifactorial disease 
It is well known that a cascade of cytotoxic events underlies neuronal death with 
different primary causes. Among these events, mitochondrial dysfunction, glutamate 
toxicity, calcium overload, formation of reactive oxygen species (ROS), and 
cytoskeletal changes play a prominent role. Although the primary cause or the factor 
which switches on the cascade of neurotoxic events in ALS is not yet known, a clear 
understanding of the various factors involved in the neurodegenerative process is of the 
utmost importance in order to develop future therapeutic strategies for treatment of 
ALS. Many of the steps in the cascade, as visualized in figure 1, can be cause as well as 
consequence and they amplify each other. This makes it very difficult to discriminate 
between primary and secondary factors in the pathogenesis of ALS. Furthermore, it can 
not be excluded that aging, altered gene products, and environmental influences play a 
prominent and possibly a primary role in this cascade inducing ALS [Eisen, 1995]. 
1.2.1 A cascade of neurotoxic events resulting in cell death 
Mitochondrial dysfunction may initiate a cascade of neurotoxic events leading to the 
cell death of motor neurons in ALS (see 1.2.2.1). Mitochondrial dysfunction results in 
energy depletion [Albin and Greenamyre, 1992; McLaughlin et al., 1998; Novelli et al., 
1988] which in turn leads to partial neuronal depolarization, causing presynaptic 
glutamate release and the relieve of the voltage-dependent Mg++ -block of NMDA 
receptors. The excitatory neurotransmitter glutamate activates two types of receptors: 
metabotropic, GMP-binding proteins coupled, receptors and ionotropic receptors, 
ligand-gated ion channels. The ionotropic receptors are divided in NMDA, AMPA, and 
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Figure l. Schematic drawing of the cascade of cytotoxic events that may underlie neuronal death 
in ALS. 
NTs=neurotrophins glut. =glutamale ree. =receptor ROS=reactive oxygen species 
kainate receptors, named after the most potent agonist. Glutamate-induced 
depolarization results in a calcium influx into the cell via NMDA-receptors, which are 
permeable to divalent cations, and occasionally via non-NMDA-receptors that are 
impermeable for calcium under normal circumstances. To protect the cell from calcium 
overload, the intracellular calcium concentration is regulated by calcium-buffering 
proteins, such as parvalbumin, calbindin D28k, and calretinin [Baimbridge et al., 1992], 
by the sequestration within organelles, such as the endoplasmic reticulum (ER) and 
mitochondria [Orrenius et al., 1989], and by the transfer to the extracellular 
environment via ion exchangers or ATP-dependent calcium pumps [Baimbridge et al., 
1992]. 
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When the energy metabolism is impaired, ATP-dependent extrusion of calcium and 
ATP-dependent storage of calcium into intracellular storage organelles is reduced, 
resulting in an increased calcium concentration A dramatic increase in the intracellular 
calcium concentration due to an increased influx, disturbed calcium buffenng, or a 
decreased functioning of ion exchangers, or indeed, a combination of these factors, 
leads to activation of proteases, calcium dependent oxidant-generating enzymes, such as 
phosphohpase A2 and mtnc oxide synthase, and endonucleases, resulting in the 
formation of ROS and eventually in cell death [Novelli et al , 1988] Moreover, uptake 
of excess calcium into mitochondria, at the cost of the proton gradient of mitochondria 
may further disturb the energy metabolism of the cell, aggravating the energy shortage 
[Montai, 1998] 
The enzymes of the electron transport chain in mitochondria are vulnerable to 
oxidative damage In addition, mitochondrial DNA is especially sensitive to oxidative 
stress, because of the lack of protective histones, the close proximity to the electron 
chain transport, and the lack of efficient DNA-repair enzymes In this way oxidative 
stress, induced by mitochondrial dysfunction, may result in an impaired ATP- synthesis 
and energy depletion [Bowling and Beai, 1995, Cassanno and Bennett, 1999] 
Furthermore, ROS formed after energy shortage or calcium overload may damage 
glutamate transporters, resulting in decreased glutamate removal from the synaptic cleft 
to surrounding glial and neuronal cells and subsequently to glutamate toxicity [Volterra 
et al , 1992] Moreover, neurofilaments, with their long half-life and a high content of 
lysine, are vulnerable to oxidative stress, resulting in an impaired axonal transport and 
accumulation of neurofilaments in the cell body in the so-called Bumna bodies [Chou et 
al, 1996], which may lead to cell death [Manette et al , 1988, Sasaki and Iwata, 1996b] 
Besides oxidative damage of neurofilament proteins, the decreased neurofilament 
transport as observed in ALS patients can also be caused by glutamate toxicity It has 
recently been described that glutamate toxicity can increase the phoshorylation of the 
side-arm domains of neurofilaments via activation of members of the mitogen-activated 
protein kinase (MAPK) family, thus resulting in decreased neurofilament transport 
[Miller et al, 2000] 
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1.2.2 Primary causes in ALS 
Vanous hypotheses, each built around one of the key players in the cascade of 
neurotoxic events, have been formulated during recent years 
12 2 1 Mitochondrial dysfunction 
There is emerging evidence that mitochondrial dysfunction is an important factor in 
the cascade of neurotoxic events as observed during pathogenesis of ALS (reviewed in 
[Beai, 1998, Cassanno and Bennett, 1999]) Morphologically changed mitochondria 
[Curti et al, 1996, Sasaki and Iwata, 1996a, Hirano et al, 1984] and defects in the 
mitochondrial electron chain transport in areas where cells die as well as in platelets 
have been found in ALS patients [Beai et al, 1993, Borthwick et al, 1999, Fujita et al, 
1996] Transferring mitochondria of ALS patients to mtDNΑ-depleted human 
neuroblastoma cells results in decreased electron transport activities, an increased 
amount of ROS, excitotoxic cell death, and abnormal calcium handling [Swerdlow et 
al, 1998] Furthermore, in the (affected) motor cortex of sALS patients the number of 
mtDNA mutations is more than 30-fold higher than in the (unaffected) temporal cortex 
[Dhahwal and Grewal, 2000] 
12 2 2 Glutamate excitotoxicity 
Glutamate is thought to play an important role in the pathogenesis of ALS 
Glutamate released by presynaptic neurons normally stimulates motor neurons and its 
synaptic actions are rapidly terminated by specific glutamate transporters on astrocytic 
and neuronal membranes surrounding the synapse [Shaw and Ince, 1997] 
Accumulation of glutamate in the synaptic cleft can initiate neurotoxic effects due to 
increased entry of calcium into the motor neurons (see 12 1) In the plasma and 
cerebrospinal fluid of ALS patients glutamate levels are increased [Plaitakis and 
Caroscio, 1987, Plaitakis, 1990] Impairment of glutamate uptake by the astrocytic 
transporters also leads to increased glutamate concentrations around the motor neurons 
The rate of transport by high-affinity glutamate transporters in spinal cord, 
somatosensory cortex and motor cortex is reduced in ALS patients [Rothstein et al, 
1992], and the level of the glutamate transporter excitatory amino acid transporter 
(EAAT) 2 protein is decreased [Bristol and Rothstein, 1996] Furthermore, 
overexpression of EAAT2 in a transgenic mouse model which closely mimics the 
neuropathological features as observed in ALS (the so-called SODI-mouse, [Gumey et 
al, 1994] leads to a dramatic delay in disease onset [Rothstein et al, 2000] Finally, the 
glutamate release inhibitor nluzole (2-amino-6-trifluromethoxy-benzothiazole) is the 
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only drug so far that appears to have a positive effect on the survival of ALS patients 
[Bensimon et al., 1994] 
12 2 3 Calcium toxicity/ autoimmunity hypothesis 
Another hypothesis formulated is that an autoimmune response may lead to calcium-
induced cell death In serum of ALS patients antibodies have been detected against L-
type voltage-gated calcium-channels [Smith et al., 1992]. The binding of these 
antibodies results in an increased calcium influx into the cell followed by cell death as 
shown in a cell line of motor neuron-like cells [Alexianu et al., 1994, Uchitel et al, 
1988] Furthermore, passive transfer of the antibodies to motor neurons in vivo results in 
an elevated calcium concentration and ultrastructural changes [Engelhardt et al, 1995] 
Motor neurons are selectively affected after increased calcium influx, which is probably 
related to the regulation of intracellular calcium concentrations as discussed above In 
this respect a prominent role of calcium-binding proteins was suggested [Alexianu et al, 
1994, Ho et al., 1996]. As motor neurons that are affected in ALS lack the calcium-
binding proteins parvalbumin and calbindin D28k [Alexianu et al., 1994], they are 
probably less able to handle the increasing amounts of intracellular calcium 
Overexpression of calbindin D28k in motor neuron hybrid cells after retroviral infection 
with calbindin D28k cDNA prevents ALS IgG-mediated toxicity [Ho et al, 1996] 
12 2 4 Oxidative stress 
In 10 to 20% of the fALS patients a mutation has been found in the SODI gene, 
suggesting an altered defence against oxidants in the cell [Rosen et al, 1993] The 
toxicity of mutant SODI could be caused by aberrant chemistry mediated by the 
misfolded aggregated mutants and/or by coprecipitation of essential component(s), such 
as protein folding chaperones [Bruening et al, 1999] However, the mutations found in 
the SODI protein induce a toxic gain of function The mutated SODI polypeptide is 
less tightly folded, resulting in aberrant copper-mediated chemistry due to greater access 
of abnormal substrates, such as peroxymtrite and hydrogen peroxide, which is normally 
an end product, to the copper atom in the active site [Beekman et al, 1993; Deng et al, 
1993] The reaction of peroxymtrite with SOD 1 results in the nitration of tyrosine and 
formation of highly reactive free radical species, such as hydroxy! radicals and 
nitronium ions [Beekman et al , 1993] and subsequently in damage to proteins, lipids 
and DNA and finally to cell death In some sALS or SODI-mediated fALS patients 
increased levels of markers of oxidative damage have been detected in the motor cortex, 
in spinal motor neurons and in cerebrospinal fluid and plasma [Bowling et al., 1993, 
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Przedborski et al, 1996, Moumen et al, 1997, Beai et al , 1997] Besides the toxic gain 
of function of the mutant SODI protein, in ALS patients the formation of SODI 
aggregates is a frequent feature [Bruijn et al, 1998, Durham et al , 1997], possibly 
leading to coprecipitation of essential components [Bruening et al, 1999] 
The mutant SOD 1 gene has been used to create an animal model that closely mimics 
the neuropathological features as observed in ALS the transgenic mouse 
overexpressing various mutant human SODI proteins [Bruijn et al, 1997, Gumey et al, 
1994] Transgenic SODI mice, such as G93A mice, in which glycine at position 93 in 
the SODI protein is substituted with alanine [Dal Canto and Gumey, 1994, Gumey et 
al, 1994], and G85R mice, in which glycine at position 85 is substituted with arginine 
[Bruijn et al, 1997], express cytoskeletal alterations, neurofilament protein 
immunoreactive aggregates, SODI aggregates, vacuolar degeneration of the anterior 
horn, atrophy and Lewy body-like inclusions in motor neurons and axons, followed by 
motor neuron death [Bruijn et al, 1997, Dal Canto and Gumey, 1994, Gumey et al, 
1994, Tu et al , 1997] The seventy of the phenotype and the age at which the transgenic 
mouse dies are related to the number of copies of the mutant human SOD 1 gene The 
high-expressor G93A mouse develops motor neuron disease with paralysis in one ore 
more limbs and spinal motor neuron loss starting at about 3 months of age They die at 
an age of 4 to 5 months [Chiù et al , 1995, Gumey et al , 1994] In the low-expressor 
G93A mouse the onset of the disease is at an age of 6,5 to 8 months [Chiù et al, 1995, 
Gumey et al , 1994, Jaarsma et al, 1996] 
12 2 5 Cytoskeletal changes 
The suggestion that changes in the cytoskeleton play a primary role in the 
pathogenesis of ALS comes from the finding that neurofilament-accumulations in motor 
neurons and proximal axons and the abnormal assembly of the neurofilament structures 
are among the most common hallmarks found in the early stages of human motor 
neuron disease (including sALS and fALS), particularly located to the anterior horn of 
the spinal cord [Hirano, 1991, Carpenter, 1968, Figlewicz et al, 1994, Chou et al, 
1996, Hirano et al, 1984, Manette et al , 1988, Sasaki and Iwata, 1996a] In addition, in 
a small number of sALS patients a mutation has been found in the NF-Η gene 
[Figlewicz et al, 1994, Al Chalabi et al, 1998, Tomkins et al, 1998] Furthermore, in 
the cell bodies of motor neurons of ALS patients phosporylated neurofilament has been 
detected [Manetto et al, 1988, Munoz et al, 1988, Sobue et al, 1990], indicating a 
blockade in the transport of neurofilaments primary to their accumulation in the cell 
body The subsequently formed ubiquinated Lewy body-like inclusions, or Bunina 
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bodies, are immunoreactive for neurofilament epitopes [Ince et al, 1998, Murayama et 
al, 1989] Transgenic mouse models with human NF-L or NF-Η overexpression show 
an excessive accumulation of neurofilaments and a decreased axonal transport, but 
without motor neuron degeneration or motor neuron death [Marszalek et al, 1996, Xu 
et al, 1993] In contrast, overexpression of human NF-Η and point-mutations of NF-L 
result in massive selective degeneration of spinal motor neurons leading to selective 
motor neuron death, abnormal accumulations of NFs, and severe neurogenic atrophy of 
skeletal muscles [Collard et al ,1995, Cote et al ,1993, Lee et al, 1994] Neurofilament 
misaccumulations may directly cause selective degeneration and death of motor 
neurons, which is even true if the neurofilament aberrations are intially provoked by 
mutant SODI Elimination of neurofilaments or decreasing the axonal amount of 
neurofilaments slows the onset and the progression of the disease in mutant SODI mice 
[Couillard-Despres et al, 1998, Williamson et al, 1998] Although it is not sure that 
neurofilament aberrations are capable to provoke motor neuron disease by themselves, 
collective evidence strongly suggests that variants in NFs are, at the least, important risk 
factors for ALS 
The monoclonal antibody Py, generated by Woodhams et al [Woodhams et al, 
1989], is suggested to be associated with the neurofilamentous and microtubular 
elements of the cytoskeleton of specific large diameter neuron populations including the 
spinal motor neurons [Brook et al, 1997, Houweling et al, 1999] After axotomy of 
Clarke's nucleus neurons, Py immunoreactivity has been shown to be one of the first 
indicators of cytoskeletal alterations in the cell body After transection of axons Py 
immunoreactivity changes even quicker and more markedly than a previously used 
early indicator of cytoskeletal alterations, the microtubuli associated protein-2 (MAP2) 
[Brook et al, 1998] It is therefore suggested that the Py antigen may be a sensitive tool 
for detection of early alterations of the cytoskeleton in affected motor neurons 
1.3 Selective vulnerability of affected motor neurons 
In ALS the motor neurons in the spinal cord and the bulbar region in the brain stem 
(lower motor neurons) and in the motor cortex (upper motor neurons, called Betz cells 
in man) are affected Remarkably, the motor neurons that control the eye movement 
(oculomotor neurons [nlll], trochlear nucleus [nIV], abducens nucleus [nVI]) and the 
motor neurons that control the pelvic floor muscles (located in Onufs nucleus in the 
sacral spinal cord) are relatively spared in ALS [Alexianu et al, 1994, Carvalho et al, 
1995] A key question in research on mechanisms underlying cell death in ALS is why 
specific motor neuron populations are affected, whereas others are spared As 
20 
Introduction 
mentioned in 1.2 there are several factors involved in the toxic cascade that eventually 
induces motor neuron death. Both the chemical and morphological characteristics 
related to these factors may determine increased vulnerability of affected motor neurons 
as compared to spared motor neurons In 1.3.1 (table 1) the contributing factors are 
listed and described The chemical and morphological characteristics underlying 
increased vulnerability of affected motor neurons may differ between affected and 
spared motor neurons during normal aging Furthermore, chemical and cellular 
characteristics may change in ALS due to the course of the disease, such as glutamate 
transporter density and transport rate. 
1.3.1 Affected motor neurons versus spared motor neurons in 
control cases or during normal aging and in ALS 
The well-known age-related decline of mitochondrial functions [Mecocci et al., 
1993] combined with the relatively high energy demand of the motor neurons makes 
these cells in particular vulnerable to energy depletion The decline in mitochondrial 
functions combined with mutations of mitochondrial DNA (mtDNA) and damaged 
mtDNA [Richter et al , 1988] may explain the delayed onset and the slow progression 
of ALS 
Furthermore, the high amount of mitochondria in motor neurons may result in 
exposure to more oxidative stress as compared to other neuronal cells, because the 
electron transport chain in mitochondria is one of the main sites for the intracellular 
generation of free radicals In spinal motor neurons and in the motor cortex mutated 
mtDNA has been found [Dhahwal and Grewal, 2000] It is likely that also spared motor 
neurons contain mutated mtDNA, but, due to other chemical or cellular characteristics 
of these cells, they may be less vulnerable 
As can be deduced from table 1, the most sinking differences between affected and 
non-affected motor neurons are found in the calcium-binding proteins and in the 
glutamate receptor density, and the density and velocity of glutamate transporters 
Glutamate toxicity occurs via NMDA and occasionally via non-NMDA receptors, that 
are both present on upper and lower motor neurons [Estevez et al , 1995] Non-NMDA 
receptors are involved in the cell death of spinal motor neurons after glutamate transport 
inhibition or energy depletion [Rothstein et al, 1993, Kaal et al., 2000], but it is still 
unknown which glutamate receptor(s) play(s) a role in cell death of cortical motor 
neurons A higher density of calcium-permeable glutamate receptors results in a higher 
response to glutamate toxicity. Spared motor neurons, such as motor neurons in the 
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Table 1. Factors that may underlie increased vulnerability of affected motor neurons 
Cellular characteristics 
Mitochondrial 
changes 
Glutamate 
receptor 
density 
AMPA 
receptor 
subumts 
Glutamate 
transporters 
Calcium-
bmding 
proteins 
S0D1-
mutations 
Cyioskcictal 
Changes 
NTs 
Trk receptorb 
Morph changes 
bTC changes 
mtDNA mutations 
NMDA 
AMPA 
KA 
GluR2 
FAAT-2 
Calbindin D28k 
Calretinin 
Parvalbumin 
NF-Η mutations 
NT-3 
BDNF 
NT^t 
NGF 
TrkA 
TrkB 
TrkC 
Upper motor 
neurons/ 
Motor cortex 
Non-
ALS 
-
Î 
1 
i 
4. 
(Bet?) 
Τ 
-
-
• 
+ 
+ 
+ 
+ 
+ 
ALS 
+ 
+ 
+ 
î 
Τ 
i 
(Bel?) 
1 
-
+ 
+ 
i 
*> 
7 
9 
·> 
Lower motor 
neurons 
Spinal cord 
Non-
ALS 
-
Τ 
4. 
4, 
(subset) 
Τ 
-
+ 
+ 
+ 
+ 
ALS 
+ 
+ 
+? 
l / T 
τ 
τ 
(subset 
) 
i 
-
+ 
+ 
i 
τ 
î 
Τ*' 
Non-afTcctcd 
motor neurons 
Non-
ALS 
-
1 
î 
τ 
1 
+ 
+ 
+ 
• 
+ 
+ 
+ 
+ 
+ 
ALS 
9 
+? 
+? 
4 
4 
_ * 
+ 
+ 
+ 
+? 
+ 
> 
't 
•> 
•» 
Refs 
32 50 96 
42 
35 
25 99 116 
101 
101 
115 116 
M 71 109 
1 54 
90 
1 41 108 
16 
KO 
80 
71 78 98 
/ increased, J- decreased, + present, - absent, = comparable with control 
*' The number of NMDA binding sites m the venti al horn of the spinal coid is decreased, 
probably due to the loss of motor neurons Nevertheless, the number ofNMDA binding sites m the 
intermediate grev is increased in ALS patients as compared to non-affected motoi neurons [Shaw 
et al, 1994b] *' The number of AMPA binding sites is comparable to the number in the motor 
cortex and decreased as compared to the number in the spinal cord [Shaw et al, 1994a] * The 
ι elative number of AMPA subumts m the non-affected motor neurons is compaiable to those m 
the affec ted motor neuron s ** The number of TrkB receptors is incieas ed in the spinal c ords of 
ALS patients, but the TrkB receptors are much less phosphorylated on tyrosine [Muloh et al. 
2000, Seeburger et al, 1993, Meyer et al, 1992] 
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oculomotor nucleus, express a lower density of NMDA receptors and a higher density 
of non-NMDA receptors as compared to affected motor neurons [Chinnery et al , 1993, 
Williams et al, 1996] The higher density of NMDA receptors in the deep layers of the 
cortex suggest an increased vulnerability of the cortical motor neurons to glutamate 
toxicity via NMDA receptors In contrast, the non-NMDA receptor density is lower in 
the affected motor neurons The initial selective vulnerability of the affected motor 
neurons in ALS can here be explained by the presence of GluR2-containing AMPA 
receptors on non-affected motor neurons and GluR2-lacking AMPA receptors on 
affected motor neurons [Williams et al , 1997] Furthermore, the number of AMPA 
receptors is increased in the spinal cord of ALS patients, suggesting an increasing 
vulnerability during the course of the disease [Shaw et al, 1994a] 
The number and transport rate of glutamate transporters on neurons and glial cells 
determine the extracellular glutamate concentration Motor neurons that arc affected in 
ALS have a higher pensomatic expression of the glutamate transporter EAAT2 as 
compared to motor neurons that are normally spared in ALS, such as oculomotor 
neurons, suggesting a higher glutamate concentration under normal conditions [Milton 
et al, 1997] As a consequence, a decreased glutamate transporter expression or 
decreased velocity, due to aberrant mRNA, as described for 65 % of the ALS cases [Lin 
et al, 1998, Nagai et al, 1998], or damage by reactive oxygen species (ROS) [Trotti et 
al , 1996], may have more consequences for affected motor neurons 
lonotropic (NMDA and non-NMDA) glutamate receptors consist of 4 or 5 subumts 
that determine the properties of these postsynaptic glutamate receptors, such as ionic 
permeability [Sommer and Seeburg, 1992] The non-NMDA AMPA-receptor, involved 
in the cell death of spinal motor neurons [Kaal et al, 2000, Rothstein et al , 1993, 
Rothstein and Kuncl, 1995], is formed by the subumts GluRl-GluR4, of which the 
GluR2 subunit determines the calcium permeability When the GluR2 subumt is 
present, which is normally the case, AMPA receptors are not calcium permeable 
[Hollmann et al, 1991] A subset of AMPA receptors on rat spinal motor neurons lack 
the GluR2 subunit [Greig et al, 2000, Pellegrini-Giampietro et al , 1997] and in human 
the GluR2 mRNA expression is low in spinal motor neurons and Betz cells (upper 
motor neurons) [Williams et al, 1997] thus resulting in calcium permeability The 
subunit distribution of the AMPA subumts on the spared motor neurons is comparable 
to that on affected motor neurons and may therefore not be responsible for the lower 
vulnerability [Williams et al, 1996] 
The absence of calcium-binding proteins in the affected motor neurons may account 
for the increased vulnerability of affected motor neurons as compared to spared motor 
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neurons that do express calcium-binding proteins [Alexianu et al, 1994, Ince et al, 
1993] In contrast, Laslo and colleagues have found that some affected motor neurons 
express calretmin and parvalbumin [Laslo et al, 2000] 
The SODI protein content in motor neurons under control conditions is much higher 
as compared to other cells in the nervous system This may reflect the presence of more 
oxidative stress in motor neurons [Nishiyama et al, 1997] As a consequence, motor 
neurons are more vulnerable to the presence of mutant SODI In G93A (SODI) 
transgenic mice, the free radical content is increased in the spinal cord, but not in the 
brain, suggesting tissue specific differences in the level of transgene expression [Liu et 
al, 1998] Differential mutant SODI expression may account for the selective 
vulnerability of the spinal motor neurons in this disease model and may also play a role 
in the selective vulnerability of affected motor neurons as compared to spared motor 
neurons in ALS 
Motor neurons possess long axons with a strong internal skeleton Therefore, the 
concentration of neurofilament proteins in the cell is relatively very high as compared to 
other neurons This leads to an increased reaction to mutations in neurofilament proteins 
or neurofilament damage through oxidative stress 
Besides the described chemical and morphological characteristics of affected versus 
non-affected motor neurons, neurotrophic factors, such as brain denved neurotrophic 
factor (BDNF), neurotrophin-3 (NT-3) and neurotrophin-4 (NT-4), and their tyrosine-
kinase (trk) receptors may contribute to the selective vulnerability of certain 
neuronpopulations to glutamate and calcium toxicity (see Fig 1) The neurotrophin 
BDNF changes the subunit composition of NMDA and non-NMDA receptors, thereby 
regulating the calcium-permeability [Glazner and Mattson, 2000] NT-3 and BDNF are 
known to increase the expression of the calcium-binding molecule D28k [Collazo et al, 
1992, Cheng and Mattson, 1994, Mattson et al, 1993, Brene et al, 2000] In aged rat 
spinal cord motor neurons mRNA of TrkB and TrkC, the receptors for BDNF and NT-3 
respectively, are decreased [Johnson et al, 1996], suggesting a role in age-related and 
possibly also disease-related motor disturbances As mentioned in table 1, theTrkB-
mediated intracellular signalling in ALS spinal cords is disturbed [Mutoh et al, 2000] 
Although TrkB is increased in the spinal cord of ALS patients [Meyer et al, 1992, 
Seeburger et al, 1993], which is possibly a compensatory response to the degenerative 
processes, TrkB is much less phosphorylated on tyrosine [Mutoh et al, 2000] 
Furthermore, BDNF- and ΝΤ-3-like immunoreactivity is decreased in motor neurons in 
spinal cord sections of postmortem tissue of ALS patients [Duberley et al, 1997, Nishio 
et al, 1998] Remarkably, the NGF- and TrkA-like immunoreactivity, normally absent 
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in motor neurons, are increased in ALS patients, suggesting a switch in neurotrophin 
dependence [Nishio et al., 1998]. The properties of neurotrophins and the observed 
changes in neurotrophin concentration and receptor density and function suggest that 
neurotrophins may play a role in the progression of ALS, even if they are not directly 
involved in the pathogenesis. 
1.3.2 Conclusion 
Chemical and cellular differences between affected and spared motor neurons in 
control cases and in ALS together determine the eventual selective vulnerability of 
upper and lower motor neurons. Mitochondria in affected upper and lower motor 
neurons contain mutated mtDNA and damaged mtDNA, resulting in energy depletion 
and subsequently in glutamate toxicity, calcium overload, oxidative stress, and 
neurofilament damage. Moreover, affected motor neurons are more sensitive to 
excitotoxicity, due to an increased number of NMDA-receptors in control cases, an 
increased number of AMPA-receptors in ALS, calcium-permeable AMPA-receptors 
and a decreased glutamate transport to surrounding glial cells. Furthermore, according 
to most literature so far, affected motor neurons lack calcium-binding proteins and are 
therefore not capable of efficient calcium handling. SODI mutations, as described in a 
number of fALS patients, and mutations of NF-Η proteins, as described in a number of 
sALS patiens, are in particular very harmfull for motor neurons, due to the high content 
of SODI and neurofilament in motor neurons. Also decreasing neurotrophin 
concentrations and changes in their receptors may influence the vulnerability of motor 
neurons. In conclusion, it is likely that the combination of characteristics of spinal and 
cortical motor neurons and factors that are changed due to the course of the disease 
underly the selective vulnerability of affected motor neurons in ALS. 
It can be deduced from table 1 that the characteristics of cortical motor neurons and 
spinal motor neurons are very much alike. The only possible difference can be noted in 
the density of glutamate receptors in ALS. This suggests that possible differential 
reactions of spinal and cortical motor neurons to the toxic cascade inducing cell death 
are likely caused by glutamate receptor density. 
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1.4 Aims of study 
In ALS, both spinal and cortical motor neurons degenerate, but in experimental 
studies in animal models most attention so far has been focussed on the spinal motor 
neurons, and methods exist to purify these motor neurons [Schnaar and Schaffner, 1981 ; 
Camu and Henderson, 1992; Kaal et al., 1997]. In order to study the degeneration and/or 
vulnerability of the cortical (upper) motor neurons (CMNs) we used a long-term in vitro 
model of slices of the rat cortex. With the use of this model we wanted to address the 
following questions: 
1 Is mitochondrial dysfunction involved in cortical motor neuron death in an 
organotypic culture model ? 
1 a What mechanism underlies malonate induced cell death of cortical motor neurons 
and is this mechanism comparable to malonate induced cell death of spinal motor 
neurons? 
lb Can neurotrophins protect cortical motor neurons against malonate induced cell 
death in the organotypic culture model? 
Common hallmarks in the early stages of ALS are neurofilament-accumulations and 
abnormal assembly of the neurofilament structures, in particular located in motor 
neurons and proximal axons in the anterior hom of the spinal cord [Hirano, 1991]. Py-
immunoreactivity, associated with the neurofilamentous and microtubular elements of 
the cytoskeleton of spinal motor neurons [Woodhams et al., 1989], is one of the first 
indicators of cytoskeletal changes in the cell body (Brook et al., 1998). Therefore, we 
also wanted to answer the following question: 
2 Can the Py-antibody be used to determine early cytoskeletal alterations in motor 
neurons of the SODI transgenic mouse 
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Abstract 
There is growing evidence that mitochondrial dysfunction is an important factor in a 
cascade of neurotoxic events as observed during pathogenesis of various 
neurodegenerative diseases. In the neurodegenerative disease amyotrophic lateral 
sclerosis (ALS) both spinal and cortical motor neurons degenerate, but in experimental 
studies most attention so far has been focussed on the spinal motor neurons. In order to 
study the role of mitochondrial dysfunction in the pathways leading to cortical (upper) 
motor neuron (CMN) death, a long-term culture system of rat cortical expiants was 
used. CMNs were visualized by immunocytochemical labeling with antibodies directed 
against non-phosphorylated neurofilament, SMI-32, and for their identification we also 
used their location in layer V of the expiant, their size, and their morphological 
appearance. In this model the effect of mitochondrial inhibition was studied through 
chronic malonate treatment. During two weeks, low doses of complex II inhibitor 
malonate, were added to the cultures twice a week. The malonate-induced chronic 
mitochondrial inhibition resulted in a dose-dependent increase of CMN death in the 
slices. Neuroprotection was achieved with the NMDA-antagonist MK-801 and the non-
NMDA-antagonist CNQX indicating the involvement of glutamate in the malonate 
induced CMN death. Furthermore, our data indicate that chronic mitochondrial 
inhibition results in CMN death, which is mediated by glutamate excitotoxicity via 
both non-NMDA and NMDA-receptors. In this respect the present in vitro approach 
may act as a model for understanding mechanisms underlying CMN death in ALS. 
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Introduction 
In neurodegenerative diseases, such as Alzheimer's disease (AD), Parkinson's 
disease (PD), Huntington's disease (HD) and amyotrophic lateral sclerosis (ALS), 
specific cells in the central nervous system degenerate over a long period In ALS, for 
instance, motor neurons located in spinal cord, brain stem, and cortex die There is 
growing evidence that mitochondrial dysfunction is an important factor in a cascade of 
neurotoxic events as observed during pathogenesis of various neurodegenerative 
diseases Abnormal mitochondria have been found in ALS [Hirano et al, 1984], and 
defects in the mitochondrial electron chain transport in areas where cells die as well as 
in platelets have been reported in patients with AD, PD, and ALS [Beai et al, 1993, 
Fujita et al , 1996, Parker et al , 1989, Parker et al , 1990, Parker et al, 1994] 
Furthermore, when mitochondria of AD, PD or ALS patients were transferred to 
mitochondrial DNA depleted human neuroblastoma cells, decreased electron transport 
activities, an increased amount of reactive oxygen species (ROS), excitotoxic cell death, 
and abnormal calcium handling were observed [Swerdlow et al , 1996, Swerdlow et al, 
1997, Swerdlow et al , 1998] In a number of ALS patients mutations have been found 
in copper/zinc superoxide dismutase (SODI), which may lead to mitochondrial 
dysfunction [Browne et al, 1998] Several mutated human SOD 1 genes have been used 
to create a mouse model for ALS [Gumey et al, 1994] In transgenic mice expressing a 
G93A mutated human SODI gene, toxicity is mediated by damage to mitochondria in 
spinal motor neurons [Kong and Xu, 1998] Mitochondrial involvement in 
neurodegenerative diseases can explain the delayed onset and the slow progression of 
these diseases It is possible that a primary genetic defect involving energy metabolism 
accelerates the decline of mitochondrial functions that accompanies normal aging 
[Mecocci et al, 1993], together resulting in a delayed onset of the disease and a slow 
progression The role of mitochondrial dysfunction and its relationship to 
neurodegenerative diseases have recently been reviewed [Beai, 1998, Cassanno and 
Bennett, 1999] 
For in vitro studies of neurodegenerative diseases, the chronic nature of cellular 
degeneration requires a culture system that allows long-term observation Organotypic 
slice cultures can be cultured up to months, and the cytoarchitecture is well-preserved 
[de Jong and Ruijter, 1989, Stoppini et al, 1991], which makes it possible to localize 
the different cell types and layers within the slices [de Jong et al , 1988] Organotypic 
slice cultures have been introduced in ALS research to study spinal motor neuron death 
in chronic toxicity models [Kaal et al , 2000, Rothstein et al , 1993] In ALS, both spinal 
and cortical motor neurons degenerate, but in experimental studies most attention so far 
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has been focussed on the spinal motor neurons and methods exist to purify spinal motor 
neurons [Schnaar and Schaffner, 1981, Camu and Henderson, 1992, Kaal et al , 1997] 
In order to study the degeneration and/or vulnerability of the cortical (upper) motor 
neurons (CMNs) we used a long-term in vitro model of slices of the rat cortex 
There is no specific immunocytochemical marker for visualization of CMNs To 
overcome this problem, the CMNs can be retrogradely labeled with a tracer injected into 
the spinal cord in vivo [Catsman-Berrevoets et al , 1980, Dijkstra et al, 1999, Dong et 
al, 1996, Joosten et al , 1996, Junger and Varon, 1997, Schreyer and Jones, 1988, 
Tseng et al , 1991, Dong et al, 1996] However, the use of retrograde tracers in long-
term cultured explants results in an irregular spot-like distribution throughout the 
various cortical layers of the expiant, because surrounding glial cells take up the tracer 
from dead labeled CMNs [Rinaman et al, 1991] Alternatively, the CMNs can be 
identified by a combination of immunocytochemical and morphological characteristics 
Immunocytochemical identification of CMNs can be accomplished by staining with 
SMI-32, an antibody against non-phosphorylated middle and heavy neurofilament that 
is especially enriched in motor neurons SMI-32 selectively stains pyramidal cells in V 
of the rat cortex [Mesulam and Geula, 1991] at postnatal day (PND) 7 However, at later 
developmental ages (PND 14 and 28), also pyramidal cells in layer III are 
immunopositive for SMI-32 [Ha et al , 1998] Because non-phosphorylated 
neurofilament is not exclusively located in CMNs of the cortex, morphological 
characteristics must be included for final identification CMNs can be recognized by 
their pyramidal shape with an apical dendrite, their location in layer V of the cortex, and 
their size [Nicolai, 1981] 
In order to develop a model for CMN death in ALS, we treated the slices chronically 
with mitochondrial complex II inhibitor malonate and determined the number of 
degenerated CMNs Chronic mitochondrial inhibition with malonate in organotypic 
spinal cord cultures has been shown to result in selective spinal motor neuron death 
[Kaal et al , 2000] In spinal motor neuron death by chronic mitochondrial inhibition 
glutamate excitotoxicity via non-NMDA receptors plays a role [Kaal et al, 2000] as is 
observed after inhibition of glutamate re-uptake by glial cells in organotypically 
cultured spinal cord [Rothstein et al , 1993, Rothstein and Kuncl, 1995] In order to 
study the role of glutamate and the involvement of NMD A and/or non-NMDA receptors 
in the cortical motor neuron death after mitochondrial inhibition, neuroprotection 
experiments were carried out with NMDA antagonist MK-801 and non-NMDA 
antagonist CNQX In this way CMN death can be compared with spinal motor neuron 
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death after chronic mitochondrial inhibition A part of this study has been published in 
abstract form [Van Westerlaak et al, 1998] 
Materials and methods 
Organotypic cultures 
Organotypic slice cultures were prepared from 1 -day-old Wistar rats according to the 
method described by Stoppini et al [Stoppini et al, 1991] In brief, the brain from 
decapitated rats was rapidly removed from the skull and the meninges were removed 
The fronto-panetal part (±3 5 mm) of each hemisphere was sliced into 350 μιτι coronal 
sections The first 5 slices (± 1 75 mm) were excluded from the experiment In all slices 
used the striatum was additionally present The slices were transferred to a Millipore 
filter (Milhcell-CM, pore size 0 4 μΜ, diameter 30 mm), 3 slices per insert The inserts 
were placed in 35 mm culture wells (Nunc) containing 1 ml of culture medium [50 % 
Minimal Essential Medium (Gibco, Scotland), 25 % Hank's Balanced Salt Solution 
(Gibco, Scotland), 25 % horse serum, 6 4 mg/ml glucose, 2 mM L-glutamine, penicillin/ 
streptomycin (100 lU/ml, 100 μg/ml)] Cultures were kept in an incubator at 37 0C with 
5 % CO2 for 4 weeks Culture medium was changed twice a week After 2 weeks in 
culture pharmacological agents were added along with the medium 
Treatment 
The cultures were chronically treated with sodium malonate for 2 weeks, in the 
doses of 3 mM, 5 mM, and 10 mM in phosphate buffered saline (PBS, pH 7 3), starting 
after 2 weeks in culture In neuroprotection experiments, (+)-5-methyl-10,ll-dihydro-
5//-dibenzo[a,d]cyclohepten-5,10-imine (MK-801) or 6-cyano-7-nitroquinoxaline-2,3-
dione (CNQX) were added to the cultures simultaneously with 5 mM malonate 
Malonate and neuroprotective agents were added twice a week, when the medium was 
refreshed Sodium malonate was obtained from Sigma, MK-801 and CNQX were 
obtained from Research Biochemical International (Natick, USA) 
Immunostaining procedures 
After 4 weeks in culture the slices were fixed with 4 % paraformaldehyde in 0 1 M 
phosphate buffer (pH 7 4, 1 h) and removed from the filters Slices were stained 
immunocytochemically using a free-floating technique After 3 rinses with PBS (pH 
7 3), the slices were incubated overnight with monoclonal mouse antibodies against 
non-phosphorylated neurofilament (SMI-32, 1 32000, Affiniti, Exeter, UK) 
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Subsequently, the slices were washed 4 times with PBS containing 0 3 % Triton-X-100 
(PBS-T) and incubated with biotynilated horse-anti-mouse antibodies (1 1000 in PBS/ 
0 2 % BSA, Vector Labs, Burlingame CA, U S A ) for 5 hr Then, after 4 washes with 
PBS-T, the slices were incubated overnight with HRP-conjugated ABC-complex 
(1 440, Vectastain*, Burlingame CA, U S A , in PBS-T, 0 2 % BSA , 0 5 M NaCl) The 
peroxidase reaction was performed with DAB-Co-Ni in 0 1 M PB (pH 7 4) (0 05 % 
3,3'-diaminobenzidine 4HC1 (Fluka), 0 024 % cobalt chloride, 0 019 % ammonium 
nickel sulphate) Finally, after 3 washes with aqua destillata, the slices were put on 
cover-glasses, dehydrated, and mounted in DePex 
For the correct determination of cortical layering in the expiants conventional Nissl-
staining technique was used 
Quantification 
Quantification of the immunohistochemically stained SM 1-32 IR CMNs was 
performed by hand-counting large, SMI-32 immunopositive cells with a pyramidal 
shaped morphology, located in layer V of the expiant Coded slides were used in 
blinded investigations The number of CMNs in the whole slice was determined after 1, 
2, and 4 weeks in culture and is presented as a percentage of the number present at the 
first week in culture (± SEM) The number of CMNs in malonate-treated slices after 4 
weeks in culture is presented as a percentage of the number present in control slices (± 
SEM) at the same time point Damaged slices, thereby missing a part of the cortex, were 
excluded from the experiments Neuroprotection is presented as the percentage of the 
difference between the malonate and the control value Results were statistically 
analyzed with Student's t-tests 
Results 
Cortical development in vitro and SMI-32 labeling 
Organotypic brain slices were cultured for four weeks During these weeks the 
development of the cortex proceeded, as shown by Nissl-staining and SMI-32 staining 
Nissl-staining showed the appearance of clearly identifiable cortical layers, that could 
be visualized after 1, 2, and 4 weeks in culture (fig la, d) 
SMI-32 staining changed with time in culture After one week in culture only 
pyramidal cells in layer V were SMI-32 positive (fig lb, c), whereas after 2 and 4 
weeks also pyramidal cells in layer III and stellate neurons in layers II, III, IV and VI 
were stained with SMI-32 (le, 0 I" layers II, III, and IV, the observed stellate neurons 
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Figure 1. a. Nissl-stained cortical expiants after one week in culture. Cortical layers are 
indicated. Bar = 200 μηι. b. Exclusive labelling of CMNs in layer V with SMI-32 labeling after 
one week in culture. Bar = 200 μτη. c. Detail of the SMI-32 positive CMNs after one week in 
vitro. The staining of the CMNs is diffuse. Bar = 50 μηι. d. Nissl-staining: the cortical layering 
remains largely unaffected after 4 weeks in culture, as compared to 1 week in vitro (fig a). Bar = 
200 μηι. e. With SMI-32 not only CMNs in layer V are stained, but also stellate neurons in other 
layer are immunoreactive after 4 weeks in vitro. Bar = 200 μηι. ƒ After 4 weeks: SMI-32: Intense 
filamentous staining of the CMNs in layer V of the cortex. The branched apical dendrite of the 
CMNs is clearly visible and the CMNs have far more neuntes than after 1 week in culture. Bar = 
50 μηι. 
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were smaller than the SMI-positive pyramidal cells in layer V. In contrast, 
immunopositive stellate neurons in layer VI were comparable in size as CMNs in layer 
V (fig. lb, c, e, f). After 4 weeks the same cell types were SM1-32 positive as after 2 
weeks, but they contained far more neurites (fig. If). Also the intensity of SMI-32 
immunoreactivity in pyramidal layer V neurons changed during culturing; the staining 
appeared to be less filamentous after the first week than after 4 weeks (fig. lc,f). With 
the use of the marker SMI-32 and the morphological definition (pyramidal shape, size, 
apical dendrite, and location in layer V of the expiant), the CMNs could be 
distinguished in the explant after 1, 2, and 4 weeks in culture (fig lb, c, e, and f). 
Chronic malonate treatment of the slices resulted in cell death and/or a less healthy 
appearance of the SMI-32 positive CMNs. CMNs present in the chronic malonate-
treated slices contained less neurites (fig. 2) and the SMI-32 staining was less intense. 
Figure 2. Photo of SMI-32 labeled CMNs in the cortical expiant after 4 weeks in vitro, a. CMNs 
in control slices are characterized by the presence of many neurites and an intense SMI-32 
immunostaining. b. In slices chronically treated for 2 weeks with 5 mM malonate CMNs have a 
less healthy appearance and contain shorter neurites. Bar = 200 μτη 
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Quantification ofSMI-32 positive CMNs in controls and after malonate treatment 
Quantification of the SMI-32 labeled CMNs in layer V of the cortical expiant was 
possible. The number of SMI-32 IR CMNs decreases only slightly in time in vitro. The 
average number of CMNs per slice after 1 week in culture was 187.9 (± 39.7). After 2 
and 4 weeks in culture the relative number of CMNs decreased to 84 % and 81 %, 
respectively, of the number present after the first week in culture (not significant). A 
chronic 2-week treatment of the slices with malonate, starting after 2 weeks in culture, 
resulted in a dose-dependent decrease of the number of CMNs after 4 weeks in culture. 
Treatment with 3 mM, 5 mM, and 10 mM malonate resulted in 37 %, 65 %, and 74 % 
CMN death, respectively (fig. 3). 
Neuroprotection 
When the slices were treated with 5 mM malonate and 2, 10, or 50 μΜ MK-801, the 
number of surviving CMNs increases dose-dependently (fig 4). Moreover, treatment of 
the slices with 50 μΜ MK-801 completely protected the CMNs against malonate 
toxicity. Treatment with CNQX also resulted in an dose-dependent increase in the 
number of surviving CMNs (fig 4). Treatment of the slices with 50 μΜ CNQX resulted 
in 13 % and treatment with 100 μΜ CNQX resulted in 42 % neuroprotection. 
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Figure 3. A chronic 2-week treatment with 3 mM. 5 mM. and 10 mM malonate. starting after 2 
weeks in culture, resulted in a dose dependent decrease in the number of CMNs in the cortical 
explants. *:ρ <0.05 
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Figure 4. Neuroprotection by MK-801 or CNQX, simultaneously added with 5 mM malonate to 
the cultures (elevation from malonate level to control level = 100 % neuroprotection). *: ρ <0.05 
Discussion 
We developed a long-term model in which CMNs can be identified and quantified at 
least during a period of 4 weeks in vitro. Nissl-staining after 1, 2, and 4 weeks in culture 
showed that the cortical developmental process as observed in vitro in the expiants 
closely resembled the in vivo development (see also[de Jong and Ruijter, 1989; Ha et 
al., 1998; Nicolai, 1981]). A chronic 2-week treatment of the cortical expiants with 
malonate, starting after 2 weeks in culture, resulted in a dose-dependent decrease of the 
number of CMNs. Neuroprotection of the CMNs could be achieved by treatment with 
CNQX and MK-801, thereby indicating that glutamate excitotoxicity via both NMDA 
and non-NMDA receptors plays a role in the malonate-induced death of cortical motor 
neurons. 
Identificat ion of CMNs 
With SMI-32 staining after fixation, the CMNs in the expiant could be identified. 
There is a remarkable similarity between the location of SMI-32 positive cells after the 
first week in culture and the in vivo location of retrogradely labeled CMNs in the cortex 
of a 4-days-old rat [Schreyer and Jones, 1988; Stanfield and O'Leary, 1985]. Whereas 
after 4 weeks in vivo only pyramidal cells in layers III and V of the cortex could be 
visualized with SMI-32 [Ha et al., 1998], we also observed immunopositive stellate 
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cells in layers II, III, IV and VI in the cortical expiants after 4 weeks in culture. 
Fortunately, layer V projection neurons are already in place at postnatal day 1 [Hicks 
and D'Amato, 1968]. Hence, in addition to the SMI-32 immunoreactivity, their location 
in the expiant, their morphological appearance, and their size could be used to identify 
the CMNs. It is therefore concluded that the criteria used result in correct identification 
of CMNs in the cortical expiants. 
Quantification of CMNs 
Quantification of the SMI-32 positive CMNs in the expiants showed a slight 
decrease in the number of CMNs. Although cell death of CMNs during development in 
vivo is small to negligible [Finlay and Slattery, 1983], the procedure leading to and 
culture of organotypic slice cultures may cause some additional cell death. The number 
of SMI-32 positive CMNs decreases (not significantly) between the first and the second 
week in culture and reaches a steady state between the second and third week in vitro. 
This is in line with results of De Jong and Ruijter [de Jong and Ruijter, 1989], who 
observed the reaching of a steady state in the number of cortical cells after 2 weeks in 
culture, following an identical decrease of cortical cells during the first 2 weeks, mainly 
due to cutting damage at the edges of the expiant. Therefore, 2 weeks in culture was 
chosen as the starting point of the chronic treatment of the slices with malonate. 
In organotypic cultures of rat spinal cord, malonate induces selectively and dose-
dependently motor neuron death. [Kaal et al., 2000]. Here, exposure to malonate led to 
decreased ATP-levels after 6 h [Kaal et al., 2000]. Also in our cortical explants, chronic 
mitochondrial inhibition resulted in a dose-dependent increase of CMN death in the 
slices. In spinal cord organotypic cultures motor neurons can be protected from cell 
death by chronic mitochondrial inhibition with malonate by riluzole and CNQX, 
thereby indicating a role of glutamate [Kaal et al., 2000]. In our cortical slices, CMN 
death can also be attenuated by glutamate receptor antagonists. 
Exposure to malonate of organotypic cultures of rat spinal cord have been shown te 
lead to decreased ATP-levels after 6 h [Kaal et al., 2000]. Defects in energy metabolism 
can result in secondary excitotoxicity [Beai et al., 1993; Beai, 1995; McLaughlin et al., 
1998; Novelli et al., 1988]. Mitochondrial inhibition leads to energy depletion and, 
subsequently, to partial neuronal depolarization. As a consequence, the protective 
voltage dependent Mg^ -block of NMDA receptors is relieved, resulting in an 
uncontrolled calcium influx. Furthermore, impaired energy metabolism prevents ATP-
dependent extrusion of calcium and ATP-dependent storage of calcium into intracellular 
storage organelles. The intracellular concentration of calcium increases dramatically, 
48 
Glutamate-mediated cortico-motoneuron death 
thereby leading to activation of proteases, lipases, and endonucleases and eventually to 
cell death [Beai et al., 1993; Beai, 1995; Novelli et al., 1988]. Mitochondrial inhibition 
can mediate glutamate excitotoxicity via non-NMDA and NMDA receptors [Beai et al., 
1993]. Whereas excitotoxicity in the striatum (in vivo) induced through MPP+ is 
mediated by NMDA-receptors [Storey et al., 1992], excitotoxicity in spinal cord slices 
induced through chronic mitochondrial inhibition or chronic glutamate re-uptake 
inhibition is mediated by non-NMDA receptors [Kaal et al., 2000];[Rothstein et al., 
1993; Rothstein and Kuncl, 1995]. Our data indicate that cell death of cortical motor 
neurons in organotypically cultured slices after chronic mitochondrial inhibition is 
mediated by both NMDA and non-NMDA receptors. 
Non-NMDA receptors play a role in the malonate-induced cell death of both spinal 
and cortical motor neurons. It has been shown that a subset of spinal motor neurons 
contains AMPA-receptors that lack the GluR2 subunit and are therefore calcium 
permeable. Whereas normally calcium can only enter the cell via NMDA receptors, 
extracellular calcium can also enter the cell neurons via the AMPA-receptors [Greig et 
al., 2000; Hollmann et al., 1991; Pellegrini-Giampietro et al., 1997]. However, 
pyramidal cells in layer V of the cortex in rat have been reported to express AMPA 
receptors that contain the GluR2 subunit resulting in low calcium permeability [Conti et 
al., 1994; Geiger et al., 1995; Kondo et al., 1997; Martin et al., 1993; Vissavajjhala et 
al., 1996]. In vivo, after axotomy a downregulation of GluR2 has been observed in 
hypoglossal nucleus and spinal motor neurons [Tang and Sim, 1997; Kennis and 
Holstege, 1997]. Since in our cortical expiants the cortical motor neurons are 
axotomized during dissection procedure, the GluR2 subunit of AMPA receptors on the 
cortical motor neurons may be down regulated. The latter may than result in an 
increased calcium permeability of the AMPA receptors and thus explain the observed 
neuroprotective effect of the non-NMDA antagonist CNQX. Another interesting 
observation in the present study is the protective effect of the NMDA-antagonist MK-
801 on the survival of the CMNs. In contrast, recent studies reported the absence of any 
neuroprotective effects of MK-801 on the survival of spinal motor neurons after 
malonate induced mitochondrial inhibition [Kaal et al., 2000]. This differential effect of 
MK-801 on the survival of cortical versus spinal motor neurons may be due to a 
differential subunit composition of the NMDA receptors located in the various motor 
neuron populations. Since the NR2d subunit protect against calcium influx and the 
NR3a subunit decreases the calcium permeability [Goebel and Poosch, 1999], a 
differential subunit composition of the NMDA receptor is of crucial importance for the 
regulation of the intracellular calcium distribution. For instance, the NR2d and NR3a 
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subunit are lacking in rat motor cortex [Sun et al, 2000], whereas in rat spinal motor 
neurons both the NR2d and NR3a subunit are expressed, together with the NR1 and 
NR2a-c subunits [Abdrachmanova et al, 2000] This may result in the differential effect 
of MK-801 on spinal versus cortical motor neurons 
In conclusion, the present in vitro approach can be used to study CMNs within the 
cortical expiant and to study CMN death in relation to chronic treatment strategies Our 
data indicate that chronic mitochondrial inhibition results in CMN death, which is 
mediated by glutamate excitotoxicity via both non-NMDA and NMDA receptors In 
this respect the present in vitro approach may act as a model for understanding 
mechanisms underlying CMN death in ALS 
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Abstract 
Chronic treatment of rat cortical slices with a relative low concentration of 
mitochondrial inhibitor malonate leads to cortical motor neuron (CMN) death In the 
neurodegenerative disease amyotrophic lateral sclerosis (ALS) corticospinal neurons, 
CMNs projecting to the spinal cord, degenerate In the present study we compared the 
effect of chronic mitochondrial inhibition on the survival of CMNs located in the dorsal 
cortical areas (including corticospinal neurons) with that on ventrally located CMNs 
(non-corticospinal neurons) in vitro In the expiant culture model used, the dorsally 
located CMNs were less vulnerable to a 2-week period of mitochondrial inhibition with 
malonate as compared to ventrally located CMNs Treatment with 5 mM malonate 
resulted in 50 % surviving CMNs in the dorsal part and only 16 % in the ventral part 
Neuroprotection of the CMNs could be achieved with co-administration of the non-
NMDA antagonist CNQX, the NMDA antagonist MK-801, or the glutamate release 
inhibitor nluzole, suggesting that chronic energy shortage leads to excitotoxicity In the 
dorsal cortical areas CNQX, MK-801, and nluzole had a neuroprotective effect on the 
CMNs, whereas in the ventral cortical areas only MK-801 was neuroprotective The 
sensitivity to energy depletion and consequently excitotoxicity may be related to 
glutamate receptor density and subunit composition in various cortical areas, but also to 
the projection length and input of CMNs in vivo The present investigation gives insight 
in mechanisms leading to excitotoxic cell death of CMNs and may therefore be 
important for the development of treatment strategies in protection and survival of 
cortical motor neurons in ALS 
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Introduction 
In the neurodegenerative disease amyotrophic lateral sclerosis (ALS), motor neurons 
in spinal cord, brain stem, and cortex degenerate. The precise mechanism that leads to 
death of these motor neurons is unknown, but it is generally accepted that glutamate, 
oxidative stress, and mitochondrial dysfunction play a role in it [Beai et al., 1993; 
Dhaliwal and Grewal, 2000; Fujita et al., 1996; Swerdlow et al., 1998]. 
Mitochondrial inhibition results in energy depletion and partial neuronal 
depolarization, which eventually leads to an uncontrolled calcium influx via NMDA 
receptors and probably also via calcium permeable non-NMDA (kainate or AMPA) 
receptors. In this way, excitotoxicity in neurodegenerative diseases, mediated through 
either NMDA or non-NMDA receptors, may be a secondary consequence of defects in 
the cellular energy metabolism [Albin and Greenamyre, 1992; McLaughlin et al., 1998; 
Novelli et al., 1988; Van Westerlaak et al., 2001]. Furthermore, mitochondrial inhibition 
disturbs the ATP-dependent extrusion of calcium and the ATP-dependent storage of 
calcium into intracellular organelles, thereby leading to an increase in intracellular 
calcium. The elevated calcium concentration leads to activation of proteases, lipases, 
nitric oxide synthase, and endonucleases and eventually to cell death. 
In ALS specific motor neuron populations are known to be affected, including those 
located in spinal cord, brain stem, and cortex, whereas others are spared. Remarkably, 
besides a difference in cytosolic calcium-binding properties, a difference has been found 
in the glutamate receptor density between affected motor neurons and those that are 
spared in ALS. The spared motor neurons, such as motor neurons in the oculomotor 
nucleus, express a lower density of NMDA receptors and a higher density of non-
NMDA receptors [Chinnery et al., 1993; Shaw et al., 1991]. In deep layers of the motor 
cortex, the density of binding sites for both NMDA and non-NMDA kainate receptors 
ligands is increased in ALS patients, whereas the density of AMPA receptors is 
comparable to that in controls [Shaw et al., 1994a; Shaw et al., 1994b; Williams et al., 
1996]. In an in vitro study it has been found that spinal motor neurons selectively 
degenerate after chronic mitochondrial inhibition with the reversible mitochondrial 
complex II inhibitor malonate. This degeneration appeared to be largely dependent on 
non-NMDA receptors [Kaal et al., 2000]. In a recent study we were able to show that 
cortical motor neuron (CMN) death in cortical slices after chronic mitochondrial 
inhibition is dependent on both NMDA and non-NMDA receptors [Van Westerlaak et 
al., 2001]. Corticospinal neurons, a subgroup of CMNs known to be involved in ALS, 
are predominantly located in the dorsal areas of the cortex: i.e. the primary motor cortex 
and in the forelimb and hind limb parts of the primary sensory cortex. 
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The aim of the present investigation was to study the response of the dorsal and the 
ventral CMNs to chronic mitochondrial inhibition and the involvement of glutamate and 
glutamate receptors in this response Therefore, neuroprotection experiments were 
carried out with the non-NMDA antagonist CNQX or the NMDA antagonist MK-801 
Furthermore, the neuroprotective effect of glutamate release inhibitor nluzole was 
studied CMNs were visualized by immunocytochemical labelling with SMI-32, an 
antibody against non-phosphorylated neurofilament, in combination with their location 
in layer V of the cortical expiant, their size, and their morphological appearance [Van 
Westerlaak et al, 2001] 
Materials and methods 
Organotypic cultures 
Organotypic slice cultures were prepared from 1-day-old Wistar rats according to the 
method described before [Van Westerlaak et al, 2001] Briefly, the rats were 
decapitated and the heads were plunged into 70 % ethanol The brain was rapidly 
removed from the skull and meninges were removed in Gey's balanced salt solution 
(GBSS, Gibco, Scotland) containing 5 4 mg/ml glucose and penicillin/ streptomycin 
(100 lU/ml, 100 μg/ml) With the use of a tissue-chopper (Mcllwain), the fronto­
parietal part (±3 5 mm) of each hemisphere was sliced into coronal sections of 350 μΜ 
The first 5 slices (± 1 75 mm) were excluded from the experiments A macroscopical 
cntenon for the fronto-parietal cortex used in the expenments was the presence of the 
striatum in the slices, recognized by the typical patchy-like structure With a soft brush 
the slices were gently transferred to a Millipore filter (Millicell-CM, pore size 0 4 μΜ, 
diameter 30 mm, 3 slices per insert) Below the filter 1 ml of culture medium was 
introduced containing 25 % Hank's Balanced Salt Solution (HBSS, Gibco, Scotland), 
25% horse serum, 50 % Minimal Essential Medium (MEM, Gibco, Scotland), 6 4 
mg/ml glucose, L-glutamine (2 mM), and penicillin/ streptomycin (100 lU/ml, 100 
μg/ml) Cultures were kept in an incubator at 370C with 5 % CO2 for 4 weeks The 
culture medium was changed twice a week 
Treatment 
Starting after 2 weeks in culture, the cultures were chronically treated with 3, 5, or 
10 mM sodium malonate in PBS (pH 7 3) for 2 weeks In neuroprotection expenments, 
(+)-5-methyl-10,l l-dihydro-5//-dibenzo[a,i/]cyclohepten-5,10-imine (MK-801), 6-
cyano-7-nitroquinoxaline-2,3-dione (CNQX), or 2-amino-6-trifluromethoxy-
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benzothiazole (riluzole) were added simultaneously to the cultures with 5 mM malonate. 
Malonate and neuroprotective agents were added twice a week, along with fresh 
medium. Sodium malonate was obtained from Sigma, MK-801 and CNQX were 
obtained from Research Biochemical International (Natick, USA), and riluzole was 
generously provided by Rhône-Poulenc Rorer (Antory, France) 
Immunostaining procedures and histology 
After 4 weeks in culture the slices were fixed for 1 h with 4 % paraformaldehyde in 
0.1 M PB (pH 7.4). Slices were removed from the filters and immunocytochemically 
stained using a free-floating technique. The slices were rinsed three times with 
phosphate-buffered saline (PBS; pH 7.3) and incubated overnight with monoclonal 
mouse anti non-phosphorylated neurofilament antibodies (SMI-32, Affiniti, Exeter, UK, 
1:32000 in PBS/ 0.2 % BSA). After 4 washes of 15 min each in PBS containing 0.3 % 
Triton-X-100 (PBS-T), the cultures were incubated with biotinylated horse-anti-mouse 
antibodies (1:1000 in PBS/ 0.2 % BSA; Vector Labs, Burlingame CA, U.S.A.) for 5 h. 
Subsequently, the slices were rinsed 4 times with PBS-T in 1 h and incubated overnight 
with HRP-conjugated ABC-complex (1:440, Vectastain*, Burlingame CA, U.S.A.; in 
PBS containing 0.2 % BSA, 0.5 M NaCl and 0.3 % Triton-X-100). The peroxidase 
reaction was performed with DAB-Co-Ni in 0.1 M PB (pH 7.4) (0.05 % 3,3'-
diaminobenzidine · 4HC1 (Fluka), 0.024 % cobalt chloride, 0.019 % ammonium nickel 
sulphate). Finally, the slices were washed 3 times with aqua destillata, put on cover 
glasses, dehydrated and mounted in DePex. 
Quantification 
Quantification of the immunohistochemically stained SMI-32 immunoreactive (IR) 
CMNs occurred by counting the cells that are large, pyramidal shaped, SMI-32 
immunopositive, and located in layer V of the expiant. Coded slides were used in 
blinded investigations. The number of CMNs was determined after 4 weeks in culture in 
control slices and chronically treated slices. The cortical expiant was divided into a 
dorsal part and a ventral part, based primarily on the length of the piai surface (Fig. 1), 
and CMNs were quantified in each part. The number of CMNs was presented as the 
percentage of the number of CMNs present in control slices (± SEM). Results were 
statistically analyzed with Student's t-tests. 
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Figure 1. Schematic drawing oj the subdivision of the cortical expiant in 2 equally sized areas 
This division was made based on the length of the piai surface. 
eg cingulate area; fr. frontal area, HL hind limb area; FL • front limb area; par: parietal area; 
Vi. visceral area, AID agranular insular cortex, dorsal part; AIV: agranular insular cortex, 
ventral part; pir piriform cortex 
Results 
Malonate toxicity 
When the cortical slices were treated with various doses of malonate a difference in 
survival was detected between CMNs located in the dorsal as compared to those in the 
ventral part of the expiant. Macroscopically, no major changes could be observed in the 
survival of the dorsal CMNs after treatment with 5 mM malonate for 2 weeks as 
compared to untreated control slices. In contrast, in the ventral part of the cortical 
explant CMN death was already macroscopically detectable after treatment with 5 mM 
malonate (Fig. 2). Quantification of the number of CMNs showed a dose-dependent 
CMN toxicity in both the dorsal and the ventral part of the expiant after chronic 
malonate treatment (Fig. 3). There was a significant difference between cell death in the 
2 parts (p < 0.05). Whereas in the dorsal part 80 % of the CMNs remained after 
treatment with 3 mM malonate, only 51 % of the CMNs survived in the ventral part of 
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Figure 2. Photo-micrograph of SMI-32 labeled CMNs in the donai and the ventral part of the 
cortical expiant in control slices and in slices chronically treated with 5 mM malonate a In the 
dorsal part of the control slices CMNs are numerous and characterized hy the presence of many 
neuntes and an intense SMI-32 immunostaming b In the ventral part less CMNs are present but 
then morphological appearance is comparable to that in the dorsal part c CMNs in the dorsal 
part of slices chronically treated for 2 weeks with 5 mM malonate have a less healthy appearance 
and contain shorter neuntes Although less numerous than in the control slices many CMNs are 
still present d In the ventral part the toxic effect of chronic malonate treatment is quite obvious 
A macroscopically detectable decrease in the number of CMNs can be observed Bar = 50 /jm 
the cortex (Fig 3) The difference in cell survival is even more prominent after 
treatment of the slices with 5 mM malonate in the dorsal part 50 % as compared to 
only 16 % of the CMNs in the ventral part survived (Fig 3) Treatment with 10 mM 
malonatc resulted in major cell death of CMNs both in the dorsal and ventral parts of 
the cortex (Fig 3) 
Neuroprotection 
To test the neuroprotective potential of several drugs affecting the glutamate 
metabolism, a dose of 5 mM malonate was used Simultaneous treatment of the slices 
with 50 μΜ NMDA antagonist MK-801 and 5 mM malonate resulted in 100 % survival 
of the CMNs in both the dorsal and the ventral half of the cortical expiant (ρ < 0 05) 
(Fig 4) Under these conditions the number of surviving CMNs was 63 % higher in the 
dorsal half and 60 % in the ventral half of the cortical explant as compared to the 
number CMNs after malonate treatment alone Treatment with 100 μΜ of the non-
NMDA antagonist CNQX and 5 mM malonatc had a different effect on the CMNs in 
the dorsal versus those in the ventral part of the expiant Significant improvement of the 
survival of CMNs with 25 % was observed in the dorsal half (p < 0 05), but not m the 
ventral half (Fig 4) Addition of nluzole to the malonate-treated expiant completely 
prevented malonate toxicity of dorsally located CMNs (p < 0 05), but not of ventrally 
located CMNs (Fig 4) 
Discussion 
In an in vitro approach it has been shown that chronic mitochondrial inhibition using 
malonate leads to death of motor neurons in both cultured spinal cord expiants 
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Figure 3 A chronic 2-week treatment with 3 mM, 5 mM, and 10 mM malonate, starting after 2 
weeks in culture, resulted in a dose-dependent decrease in the number of CMNs in the cortical 
expiants in both dorsal and ventral part. Nevertheless, the decrease in number of CMNs in the 
ventral part is significant higher than in the dorsal part after treatment with 3 and 5 mM 
malonate Treatment with 10 mM malonate resulted in a comparable amount of cell death in both 
the dorsal and the ventral half of the expiant. *: p<0.05 
[Kaal et al., 2000] and cortical explants [Van Westerlaak et al., 2001; Van Westerlaak et 
al., 1998]. In ALS spinal motor neurons and corticospinal neurons, pyramidal layer V 
neurons (CMNs) located in the dorsal part of the cortex, are primarily affected. 
Therefore, we expected a similar reaction to chronic mitochondrial inhibition in vitro. 
However, whereas non-NMDA receptors are involved in the cell death of both spinal 
motor neurons [Kaal et al., 2000] and dorsal CMNs, also NMDA receptors apparently 
play a role in the cell death of the dorsal CMNs. In contrast, the cell death of ventral 
CMNs occurs via NMDA, but not non-NMDA, receptors. The differential involvement 
of NMDA and non-NMDA receptors in the cell death of spinal motor neurons and 
dorsal and ventral CMNs may be due to differences in subunit composition of the 
receptors [Shaw et al., 1994b; Williams et al., 1996], or to differences in receptor 
density. The subunit composition determines the calcium permeability of glutamate 
66 
Differential cortico-motoneuron vulnerability 
(A 
160 
140 
120 
O 100 
(Λ 
MK-801 CNQX riluzole 
mal 
Figure 4. Neuroprotection of MK-801 (50 μΜ). CNQX (100 μΜ), and riluzole (10 μΜ). 
simultaneously added with 5 mM malonate to the cultures resulted in an increase in the number 
ofCMNs in both dorsal and ventral part of the cortical expiant. After treatment with MK-801 the 
number increased in both ventral and dorsal part of the slices, whereas after treatment with 
CNQX or riluzole only the number increased in the dorsal part. *: p<0.05 
receptors. In general, AMPA receptors are not permeable for calcium, due to the 
presence of the GluR2 subunit. AMPA-receptors that lack the GluR2 subunit are, like 
NMDA receptors, calcium-permeable [Greig et al., 2000; Hollmann et al., 1991; 
Pellegrini-Giampietro et al., 1997]. In NMDA receptors the NR2d subunit protects 
against calcium influx and the NR3a subunit decreases the calcium permeability 
[Goebel and Poosch, 1999]. 
It has been shown that the glutamate receptor density and subunit composition of 
both NMDA-receptors [Munoz et al., 1999; Sun et al., 2000] and AMPA-receptors 
[Martin et al., 1993] differ between spinal cord and cortex and between several cortical 
areas in rat [Martin et al., 1993; Sun et al., 2000; Zilles et al., 1991] and in monkey 
[Munoz et al., 1999] in vivo. The GluR2 subunit is absent in the AMPA receptors of a 
subset of spinal motor neurons [Greig et al., 2000] and its expression is low on human 
spinal motor neurons and Betz cells (upper motor neurons) [Williams et al., 1997]. 
Nevertheless, GluR2 is present on all pyramidal layer V cells (CMNs) in all cortical 
areas in rat [Conti et al., 1994; Geiger et al., 1995; Martin et al., 1993; Vissavajjhala et 
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al, 1996] The NR2d and NR3a subumts are expressed in the spinal cord and in the 
piriform cortex, but they are absent in the motor cortex [Abdrachmanova et al, 2000, 
Sun et al, 2000] In our cortical explants the primary motor cortex is located in the 
dorsal part and the piriform cortex in the ventral part 
From the absence of NR2d and NR3a in the motor cortex the involvement of 
NMDA-receptors in the malonate-induced cell death of the dorsal CMNs was expected 
Our results demonstrated neuroprotection with NMDA antagonist MK.-801, suggesting 
that NMDA receptors are indeed involved Because the GluR2 subunit of the AMPA 
receptor is present on all CMNs, resulting in calcium impermeable AMPA receptors, no 
effect of non-NMDA antagonist CNQX was predicted Nevertheless, we found 
neuroprotection of the dorsal CMNs by CNQX, indicating a role for AMPA-receptors in 
the malonate-induced cell death Here, it may be that a subset of our cultured dorsal 
CMNs express AMPA receptors lacking the GluR2 subunit, like has been found for 
human upper motor neurons [Williams et al , 1997] It has been shown that axotomy in 
vivo downregulates the GluR2 subunit expression [Tang and Sim, 1997] The 
outgrowing corticospinal tract axons that have reached cervical and thoracic levels in 
the spinal cord at postnatal day 1 [Gnbnau et al, 1986, Joosten et al, 1987] are 
axotomized during the dissection procedure which may result in GluR2 downregulation 
and subsequently in calcium permeability of the AMPA receptors on the dorsal CMNs 
The NMDA receptors of ventral CMNs in the piriform cortex express the NR2d and 
NR3a subunit [Sun et al, 2000] and are therefore expected to be less permeable for 
calcium Remarkably, we still find an effect of MK.-801 on the survival of the ventral 
CMNs This may be the result of a higher density of NMDA receptors It has been 
found that affected motor neurons express a higher density of NMDA receptors than 
spared motor neurons, and that the density of NMDA receptors in the deeper layers of 
the motor cortex of ALS patients is increased [Chinnery et al, 1993, Shaw et al, 1991, 
Shaw et al, 1994a] 
Since cortical motor neurons that are affected in ALS are located in the dorsal part of 
the expiant, we hypothesized that those motor neurons would be more vulnerable to 
chronic mitochondrial inhibition as compared to CMNs located in the ventral part 
Surprisingly, the opposite was observed in our study the ventrally located CMNs 
appeared to be more vulnerable As stated above, a higher density of NMDA receptors 
on ventral CMNs as compared to the dorsal CMNs may underlie this higher 
vulnerability Furthermore, the results may be influenced by the culturmg procedure 
Axotomy of afferent and efferent connections of the cortical tissue may affect the 
receptor subunit composition Moreover, the plasticity of dorsal CMNs may be higher 
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than the plasticity of ventral CMNs, because corticospinal neurons have not yet reached 
their target area at postnatal day l[Joosten et al., 1987], whereas ventral CMNs have 
already established synaptic connectivity in vivo prior to dissection [Gribnau et al., 
1986]. 
In conclusion, in the present study we show variations in the motor neuron 
populations situated within the same cortical expiant with respect to the reaction to 
chronic mitochondrial inhibition. The present investigation gives a first indication for 
the role of glutamate receptors during cell death of corticospinal neurons and may 
therefore be important for the development of treatment strategies in protection and 
survival of these motor neurons in neurodegenerative diseases, such as ALS. 
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is attenuated by NT-4, but not by BDNF or NT-3 
Malonate-induced cortico-motoneuron death is attenuated by NT-4, but not by 
BDNF or NT-3 
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Abstract 
Neurotrophins are promising candidates to slow the progression of amyotrophic 
lateral sclerosis (ALS), a neurodegenerative disease in which spinal and cortical motor 
neurons selectively degenerate In a long-term in vitro model malonate-induced toxicity 
and cell death of motor neurons have been demonstrated Here we studied the 
neuroprotective effect of BDNF, NT-3, and NT-4 on the cell death of cortical motor 
neurons in an organotypic culture model after chronic mitochondrial inhibition with 
malonate Our data show that NT-4 completely prevents malonate-induced toxicity, 
whereas BDNF or NT-3 had no neuroprotective effect In clinical trials for ALS, 
predominantly focussed on the survival of spinal motor neurons, BDNF has already 
been tested with disappointing results, our results suggest that NT-4 may be a better 
neurotrophin to prevent motor neuron loss 
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Introduction 
It is well known that neurotrophins play a pivotal role during development of motor 
neurons [Oppenheim, 1996], as well as in regeneration after injury of the central 
nervous system [Giehl and Tetzlaff, 1996, Tetzlaff et al , 1994] In culture, motor 
neurons can only survive for a very short time without addition of neurotrophic factors 
The survival of for instance cultured rat spinal motor neurons is increased at low 
concentrations of the neurotrophins brain-denved neurotrophic factor (BDNF), 
neurotrophin -3 (NT-3) and neurotrophin-4 (NT-4) [Henderson et al, 1993, Hughes et 
al, 1993, Kaal et al, 1997] Interestingly, spinal motor neuron death after inhibition of 
the glutamate transporter in organotypic spinal cord cultures is prevented by NT-4 but 
not by BDNF and NT-3 [Corse et al, 1999] Furthermore, NT-4 promotes survival in 
primary cultures of rat cortical motor neurons in vitro, whereas BDNF and NT-3 show 
no effect [Junger and Varon, 1997] 
In the neurodegenerative disease amyotrophic lateral sclerosis (ALS), motor 
neurons in spinal cord, brain stem, and cortex degenerate Mitochondrial dysfunction 
appears to be an important factor in a cascade of neurotoxic events underlying this 
degeneration [Beai et al , 1993, Fujita et al, 1996] In ALS in vitro research most 
attention has been focussed on spinal motor neurons so far The aim of the present study 
was to investigate the neuroprotective effect of neurotrophins BDNF, NT-3 and NT-4 
on cortical motor neurons (CMNs) after chronic mitochondrial inhibition in a long-term 
in vitro model of rat cortical expiants Furthermore, the selectivity of the 
neuroprotective effect was investigated on corticospinal neurons, a subgroup of CMNs 
that are primarily affected in ALS, as compared to CMNs not projecting to the spinal 
cord Corticospinal neurons are CMNs located in the dorsal half of the cortex [Dijkstra 
et al, 1999] We have previously shown that chronic mitochondrial inhibition leads to 
CMN death in vitro [Van Westerlaak et al, 2001] Mitochondrial inhibition results in 
energy depletion and partial neuronal depolarization, disturbs the ATP dependent 
extrusion of calcium and sodium and affects the ATP-dependent pumping of calcium 
into intracellular organelles [Beai et al, 1993] This results in an increased intracellular 
calcium concentration and subsequently in activation of proteases, lipases, and 
endonucleases and eventually to cell death [Beai et al , 1993, Novelli et al, 1988] It is 
known that neurotrophic factors NT-3 and BDNF can protect against calcium- and free 
radical-mediated toxicity following mitochondrial inhibition [Mattson et al, 1993] and 
may therefore be neuroprotective for the CMNs in our chronically malonate-treated 
cortical expiants 
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Materials and methods 
Organotypic cultures 
Organotypic cortical slice cultures were prepared as previously described [Van 
Westerlaak et al., 2001]. Briefly, the fronto-parietal part (± 3.5 mm) of the brain from 
1-day-old Wistar rats was sliced into 350 μιτι coronal sections with the use of a tissue-
chopper (Mcllwain). The first 5 slices (± 1.75 mm) were excluded from the 
experiments. The slices were collected in Gey's balanced salt solution (GBSS; Gibco, 
Scotland) containing 5.4 mg/ml glucose and gently transferred to a Millipore filter, 3 
slices per insert (Millicell-CM; pore size 0.4 μΜ, diameter 30 mm). Below the filter 1 
ml of culture medium was introduced containing 25 % Hank's Balanced Salt Solution 
(HBSS) (Gibco, Scotland), 25% horse serum, 50 % Minimal Essential Medium (MEM) 
(Gibco, Scotland), and with glucose (6.4 mg/ml) and L-glutamine (2 mM). Cultures 
were kept in an incubator at 370C with 5 % CO2 for 4 weeks. Culture medium was 
changed twice a week. 
Treatment 
Starting from 2 weeks in culture, the expiants were chronically treated for 2 weeks 
with 5 mM sodium malonate in phosphate-buffered saline (PBS) or PBS alone (control 
slices), twice a week. In neuroprotection experiments, BDNF (1-100 ng), NT-3 (1-100 
ng), or NT-4 (1-100 ng) was co-administered with sodium malonate. Sodium malonate 
was obtained from Sigma; BDNF, NT-3 and NT-4 were obtained from Regeneron 
Pharmaceuticals. 
Immunostaining procedures and histology 
After 4 weeks in culture the slices were fixed with paraformaldehyde (4 % in 0.1 M 
PB) and processed for immunocytochemistry, using a previously described protocol 
optimized for free-floating staining of cultured slices [Van Westerlaak et al., 2001]. 
Primary antibodies used were monoclonal mouse anti-non-phosphorylated 
neurofilament antibodies SMI-32 (1:32000; Affiniti, Exeter, UK) or polyclonal rabbit 
antibodies raised against rat full-length TrkB receptors (1:2000; anti-TrkB84-104, 
Amgen Inc., Thousand Oaks CA, U.S.A.). Secondary antibodies used were biotinylated 
horse-anti-mouse antibodies for the SMI-32 staining (1:1000; Vector Labs, Burlingame 
CA, U.S.A.) or biotinylated goat-anti-rabbit antibodies for the TrkB staining (1:1000; 
Vector Labs, Burlingame CA, U.S.A.). All antibodies were diluted in PBS containing 
0.3% Triton-X-100 and 0.2 % bovine serum albumin. For the TrkB staining 10% 
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normal rat serum was added to the primary antibody diluent. Immunoreactivity was 
revealed using the standard Vectastain® ABC kit (1:440) with DAB as a chromogen. 
Quantification 
Quantification of CMNs occurred by hand-counting the cells that are large, SMI-32 
immunopositive, with a pyramidal morphology, and located in layer V of the cortex 
[Van Westerlaak et al., 2001] as verified in Nissl-stained alternate sections. The cortical 
expiant was virtually divided into a dorsal part and a ventral part, based primarily on the 
length of the piai surface, and CMNs were quantified in each part. The number of 
CMNs was presented as the percentage of the number of CMNs present in control slices 
(± SEM). Results were statistically analyzed with Student's t-tests. 
Results 
Identification of the CMNs 
In the cortical slices the CMNs could be identified as large, pyramidal shaped, SMI-
32 immunopositive neurons with an apical dendrite. They were exclusively located in 
layer V of the cortical expiant (Fig. la). The CMNs were also immunopositive for 
TrkB, the receptor for BDNF and NT-4 (Fig lb). 
Matonaie toxicity and neuroprotection 
A chronic 2-week treatment of the cortical slices with 5 mM sodium malonate 
resulted in cell death of about 50 % of the CMNs. Addition of NT-4 (1-100 ng) resulted 
in a bell-shaped curve of the increase in the number of surviving CMNs with an optimal 
dose of 10 ng NT-4 (Fig. 2a). When NT-3 (1-100 ng) or BDNF (1-100 ng) were added 
to the cultures, simultaneously with malonate, no neuroprotection was noted (data not 
shown). In a separate series of experiments in order to compare the effect of NT-3, NT-
4, and BDNF, the administration of NT-4 (10 ng) to cultures treated with 5 mM 
malonate resulted in a survival of CMNs of 93 % of the number of CMNs present in the 
control slices (Fig. 2b). At the same time, the addition of similar amounts of NT-3 (10 
ng) or BDNF (10 ng) to the malonate-treated cortical slices had no neuroprotective 
effect. The number of CMNs after NT-3 and BDNF addition was 58 % and 41 % of the 
number present in the control slices, respectively (Fig. 2b). In order to study the 
neuroprotective effects on corticospinal (CS) neurons versus the non-corticospinal (non-
CS) neurons, the number of CMNs in the dorsal half (CS) and ventral half (non-CS) of 
the expiant was quantified. Then NT-4 shows complete neuroprotection against 
malonate toxicity of the CS as well as the non-CS neurons in the dorsal and ventral part 
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Figure 1. Photo-micrograph ofSMI-32 or TrkB labeled CMNs in the cortical explant in control 
slices, a. CMNs in control slices are characterized by the presence of many neuntes and an 
intense SM1-32 immunostaining. b. Staining of the control slices with antibodies against TrkB 
shows that TrkB receptors are abundantly present on the CMNs. Bar = 50 μm 
of the expiant (Fig. 2c). In the same experiment addition of NT-3 resulted in the absence 
of any neuroprotective effect on the survival of the dorsal and ventral CMNs (Fig. 2c). 
Discussion 
We studied the neuroprotective effect of neurotrophins BDNF, NT-3 and NT-4 on 
CMNs in an organotypic cortical slice culture after selective cell death caused by a 
chronic 2-week treatment with 5 mM malonate. Co-administration of NT-4 with 
malonate, but not NT-3 or BDNF, significantly improved CMN survival during chronic 
mitochondrial inhibition. Treatment with various doses of NT-4 showed a bell-shaped 
curve of the increase in the number of surviving CMNs, with an optimal survival at 10 
ng NT-4. 10 ng NT-4 completely prevented malonate toxicity in both dorsal and ventral 
half of the expiant. 
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In organotypic cultures of rat spinal cord or cortex, malonate induces a selective, 
dose-dependent motor neuron death [Van Westerlaak et al., 2001; Kaal et al., 2000]. 
TrkB and TrkC, receptors for BDNF, NT-4 and for NT-3 respectively, are both present 
on CMNs [Fryer et al., 1996; Lamballe et al., 1991]. Application of BDNF, NT-4, and 
NT-3 in vivo following a lesion results in neuroprotection of spinal and cortical motor 
neurons [Koliatsos et al., 1993; Yan et al., 1993; Giehl and Tetzlaff, 1996; Tetzlaff et 
al., 1994]. In vitro BDNF, NT-4, and NT-3 increase the survival of isolated spinal motor 
neurons [Henderson et al., 1993; Hughes et al., 1993; Kaal et al., 1997]. BDNF can 
affect the subunit composition of NMDA receptors, involved in both dorsal and ventral 
CMN death, and non-NMDA/ AMPA receptors, involved in dorsal CMNs death [Kaal 
et al., 2000; Van Westerlaak et al., 2001]. This results in a changed calcium 
permeability and finally in a smaller number of apoptotic cells [Glazner and Mattson, 
2000; Brene et al., 2000]. Furthermore BDNF and NT-3 are able to increase the 
intracellular calcium-binding molecule D28k calbindin [Collazo et al., 1992; Mattson et 
al., 1993], thereby reducing possible calcium overload. Therefore, we expected a 
neuroprotective effect of BDNF, NT-4, and NT-3 on the CMNs in our expiants. 
However, only NT-4 was neuroprotective, but not BDNF or NT-3. At the dose of 10 ng 
NT-4 completely prevented malonate-induced CMN death in both the dorsal (CS) and 
the ventral (non-CS) part of the cortical expiant. These observations are in line with the 
findings of others, who found that NT-4 had an effect on the survival of retrogradely 
labeled corticospinal cells in primary (short-term) cultures, whereas BDNF and NT-3 
did not [Junger and Varon, 1997]. Moreover, it has been shown that NT-4, but not 
BDNF or NT-3, had a neuroprotective effect on the survival of spinal motor neurons in 
organotypic spinal cord slice cultures after glutamate re-uptake inhibition, a culture 
model for ALS [Corse et al., 1999]. The effect of NT-4 on the survival of corticospinal 
cells occurs mainly through astroglial cells [Junger and Junger, 1998], that are also 
present in our cortical expiants, whereas the prevention of cell death of isolated spinal 
motor neurons in vitro by both BDNF and NT-4 occurs in the absence of glial cells 
[Henderson et al., 1993; Hughes et al., 1993; Kaal et al., 1997]. This suggests that, 
although they exert their effect through the same Trk-receptor, the eventual effect of 
BDNF and NT-4 on the survival of spinal and cortical motor neurons differs in the 
presence or absence of glial cells. The existence of two different Trk-B receptors on 
glial and neuronal cells, the truncated gpl45trkB and the full-length gp95trkB receptor 
respectively, may contribute to the differential effect of NT-4 and BDNF [Roback et al., 
1995]. The presence of truncated Trk-B receptors reduces the response of the full-length 
Trk-B receptor to BDNF [Al Chalabi et al., 1998]. Nevertheless, the neuroprotective 
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effect of NT-4 is not reduced and both NT-4 and BDNF can bind to the two types of 
Trk-B receptors, leaving the precise mechanism underlying the observed differential 
effect unclear. 
NMDA receptors are known to be involved in the malonate-induced cell death of 
both CS neurons in the dorsal and non-CS neurons in the ventral half of the expiant. We 
therefore suggest that the neuroprotective effect of NT-4 is due to a direct action of this 
neurotrophin on NMDA-receptors. By changing the NMDA-receptor subunit 
composition and/ or NMDA receptor density, NT-4 may change the vulnerability to 
excitotixicity and the calcium influx of both dorsal and ventral CMNs. Furthermore, 
NT-4 may be able to increase intracellular calcium-binding proteins, thereby reducing 
the intracellular calcium. As mentioned before, comparable properties have been 
reported for BDNF and NT-3 in other studies [Mattson et al., 1993; Glazner and 
Mattson, 2000]. 
In conclusion, our data indicate that NT-4, but not BDNF or NT-3, increases the 
survival of cortical motor neurons after chronic mitochondrial inhibition in vitro. In our 
cortical culture model for the cell death of cortical motor neurons and in a culture model 
for the cell death of spinal motor neurons [Corse et al., 1999] it has been shown that 
BDNF has no neuroprotective effect. Based on these results it is not surprising that 
BDNF treatment of ALS patients in clinical trials did not result in a positive effect. 
Moreover, we suggest that NT-4 may be considered a better candidate for prevention of 
cortical as well as spinal motor neuron loss in ALS. 
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Abstract 
Transgenic mice (G93A) carrying the human amyotrophic lateral sclerosis linked 
superoxide dismutase 1 (SODI) mutations develop a motor neuron disease resembling 
human ALS. The affected motor neurons are characterized by the presence of cellular 
alterations. The antigen recognized by the monoclonal antibody Py is suggested to be 
associated with the neurofilamentous and microtubular elements of the cytoskeleton of 
specific neuron populations including the spinal motor neurons. The aim of the present 
study was to measure changes in the relative Py-immunoreactivity per identified 
Choline-Acetyl-Transferase (ChAT)-inimunoreactive motor neuron during the disease 
progression. The relative Py-immunoreactivity of identified spinal motor neurons was 
measured on double stained (Py and ChAT) motor neurons using a digital imaging 
system coupled to an inverse microscope. A significant decrease of Py-
immunoreactivity was already noted in the pre-symptomatic stages of the disease even 
before the onset of massive motor neuron degeneration. It is concluded that the Py-
antibody detects early cytoskeletal abnormalities related to neurodegenerative changes 
in spinal motor neurons of transgenic SODl-(G93A) mice. 
87 
Chapter 5 
Introduction 
The neurodegenerative disease Amyotrophic lateral sclerosis (ALS) is characterized 
by a selective loss of upper and lower motor neurons Although the cellular mechanisms 
underlying neurodegeneration in ALS are not fiilly understood, carefull biochemical and 
morphological analysis have shown that the selective motor neuron death is possibly 
related to a deficiency in target-derived neurotrophic factors [Anand et al , 1995, 
Martin, 1999, Van Westerlaak et al, 2001] At the microscopical level it was shown that 
degenerating or a-trophic motor neurons in ALS undergo chromatolysis which is 
followed by a progressive cytoplasmic and nuclear condensation Affected motor 
neurons show cytoskeletal pathology in the form of neurofilamentous abberations and 
accumulations in the neuronal cell body and axon [Kato et al, 1987, Martin, 1999, 
Munozetal, 1988] 
The animal model that closely mimicks the neuropathological features as observed 
in ALS patients is the transgenic mouse overexpressing human superoxide dismutase-1 
(SODI) mutations [Bruijn et al, 1997, Gumey et al , 1994] The overexpression of the 
human SODI with a glycine 93 - alanine mutation (G93A) resulted in mice with ALS-
hke symptoms paralysis in limbs and severe loss of motor neurons in the spinal cord 
[Gumey et al, 1994] Closer pathological analysis of the S0D1-(G93A) mice demon-
strated progressive changes in the spinal cord cytoskeletal alterations and presence of 
neurofilament protein-immunoreactive aggregates, SODI aggregations, vacuolar 
degeneration of the anterior horn and atrophy as well as the presence of Lewy body-like 
inclusions in neurons and axons which is followed by motor neuron death [Dal Canto 
and Gumey, 1997, Gumey et al, 1994] 
The monoclonal antibody Py was generated by Woodhams et al [Woodhams et al, 
1989] by immunizing mice with a glycoprotein fraction isolated from P21 rat 
hippocampus Py, an IgM isotype antibody, recognizes a developmentally regulated 146 
kDa glycoprotein in the rat central nervous system (CNS) In various studies it was 
shown that Py stains predominantly the penkarya and main dendrites of large neurons 
as well as some populations of axons [Brook et al, 1997a, Brook et al, 1997b, Fonseca 
et al, 1992, Houweling et al, 1999, Woodhams et al, 1989] In the spinai cord of the 
normal adult rat, Py-IR was detected in almost all laminae, in particular throughout the 
cell bodies and dendrites of the large motor neurons located in Rexed lamina IX 
[Houweling et al, 1999] as well as the Clarke's column neurons [Brook et al, 1997b] 
Py-IR is absent in non-neuronal elements such as glia, ependymal cells or endothelial 
cells [Houweling et al , 1999, Woodhams et al , 1989] Recent light- and elec-
tronmicroscopic studies in the adult rat spinal cord suggest that the Py-antigen is 
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associated with the neurofilamentous and microtubular elements of the cytoskeleton of 
specific populations of neurons [Brook et al., 1997a]. 
The characteristic localization of Py might have important implications because it is 
known that cytoskeletal markers in particular are usefull for studies on re-organization 
after injuries, such as axotomy [Bisby and Tetzlaff, 1992; Brook et al., 1997b; Brook et 
al., 1998; Calvert et al., 1987]. For instance, after unilateral transection of the 
rubrospinal tract at low thoracic levels, a significant reduction in Py-immunoreactivity 
was observed in the red nucleus neurons from 7 days postoperative [Brook et al., 1998]. 
To further assess the possible usefulness of Py as a tool for cell body changes, 
densitometric analysis of altered Py-IR has been compared with that of microtubule 
associated protein-2 (MAP2) in Clarke's nucleus following axotomy [Brook et al., 
1997b]. Alterations of MAP2-IR in Clarke's nucleus were later in onset, slower to 
develop and less marked as compared to the changes in Py-IR [Brook et al., 1997b].It is 
therefore suggested that the differential distribution of the Py antigen in the CNS and its 
rapid and long-lasting loss makes the Py antibody a sensitive tool for studying novel 
and early cellular changes of selected neuron populations. In the present study it was 
hypothezised that the Py antibody can be used to detect early cellular changes in 
degenerating spinal motor neurons of transgenic SODl-(G93A) mice. 
Materials and methods 
The transgenic animals used in this study were heterozygotic hSOD 1 carriers with a 
glycine93-alanine mutation (G93A). The strain is registered as B6SJL-TgN(SODl-
G93A)lGurd' (The Jackson Lab., Bar Harbor ME USA) containing a reduced copy 
number of hSOD 1. In our animal facility, mice were backcrossed to FVB background, 
by mating hemizygotic transgenic males with outbred FVB females (Harlan, Zeist The 
Netherlands). Transgenic progeny was identified by polymerase chain reaction (PCR) of 
tail DNA with primers specific for hSODl [Rosen et al., 1993]. The transgenic mice 
derived from The Jackson Lab as well as transgenic FVB backcrosses began to develop 
clinical symptoms at 24-32 weeks of age. Initially they had difficulties in lifting the 
hindlimbs when lifted by their tails, followed by severe paralysis during the final stages 
of the disease. In the present study a total of 13 mice were used, both transgenic and 
non-transgenic (control) animals. The mice were divided into three age-classes, based 
upon the disease progression as previously reported [Dal Canto and Gumey, 1997; 
Jaarsma et al., 1996]: Age class I: < 15 weeks, presymptomatic stage (N=4, age at 
perfusion 11.5 weeks); age class II: intermediate stage between 15 and 24 weeks old 
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(N=4, age at perfusion 19.5 weeks), and age class III: final (end)-stages of disease 
(N=5, age at perfusion 32.5 weeks). 
After anaesthesia (200 ul Nembutal, i.p.) the animals were intracardially perfused: 
first with phosphate buffered saline (PBS) pH 7.3 with Heparin (20IE/ml) for 30 sec, 
followed by fresly prepared 4% paraformaldehyde (PFA) in 0.1 M phosphate buffer 
(PB) pH 7.3 for 4 min. Spinal cords were dissected and post-fixed overnight in 4% PFA 
in 0.1 M PB at 4 0C. Individual segments of the lumbar enlargement (L1-L3) were 
cryoprotected and frozen in isopentane cooled by liquid nitrogen and stored at -70 0C. 
Serial transverse cryo-sections (10 urn) of the lumbar spinal cord were mounted on 
formalin/gelatin coated glass coverslips dyhydrated in 100% acetone ( 2 x 5 min) and 
then air dried. Non-specific binding sites were blocked after incubation in a solution 
containing PBS, 50 mM glycine, 0.5% gelatine, 1% bovine serum albumine (BSA) and 
0.1 % sodiumazide, for 30 min. After this, the sections were incubated in a mixture of 
monoclonal antibody Py (supernatant 1:25 [Woodhams et al., 1989]) and polyclonal 
anti-Choline-Acetyl-Transferase (ChAT) (1:25, Chemicon) for 22 hours. The antibodies 
were diluted in 0.1 M PB containing 0.2% BSA and 0.1% sodium azide. After washing 
in 0.1 M PB the sections were incubated in the second antibodies. First the sections 
were incubated in donkey anti-goat IgG conjugated to AMC A (Jackson) (1:50, 1 hour) 
for visualization of the ChAT-antigen. Then possible aspecific staining was blocked by 
incubation in 5% Normal Goat Serum (NGS) for 1 hour. Finally, the antibody 
recognized by Py was visualized by subsequent incubation in goat anti-mouse-IgM 
conjugated to biotine (1:200, Vector) in 2% NGS for 1 hour and streptavidine 
conjugated to FITC (1:100, DAKO). Occasionally alternate sections were incubated 
with a polyclonal antibody rabbit anti-ubiquitin (1:100) (DAKO) followed by 
biotynilated Goat anti-rabbit IgG in 2% NGS and finally steptavidine conjugated to 
FITC. The relative Py-IR of ChAT/Py double-stained motor neurons in the spinal cord 
was measured using a digital imaging system (Quantimet, Leica) coupled to an inverse 
microscope (Leica) with epifluorescent equipment and filter sets appropriate for AMCA 
and FITC. A cooled CCD-camera in the linear range was used to minimize incorrect 
quantification of the Py pixel intensity. First, the ChAT-positive neurons in the ventral 
part of the spinal cord sections (lamina IX) were defined as motor neurons. The number 
of ChAT-positive motor neurons per section could now easily be determined. Then 
from each individual motor neuron the intensity of the Py-staining was determined. In 
order to correct for changes in cell volume (due to for instance cell swelling) the 
absolute intensity of the Py-staining per motor neuron is measured per urn2. Minimal 
detectable amounts of Py-IR were defined as 0, whereas the maximal Py-IR was defined 
90 
Cellular changes in motoneurons as revealed by monoclonal antibody Py 
as 100. For each condition the individual Py-IR was measured of at least 50 ChAT-
immunopositive motor neurons. 
Results 
In the lumbar spinal cord sections, ChAT-IR large motor neurons are present and 
located in the ventromedial and ventrolateral parts (lamina IX) of the anterior horn 
(Fig.lA). A few small cells situated around the central canal and located in the dorsal 
hom also showed ChAT-IR. In the motor neurons ChAT-staining was spread equally 
throughout the cytoplasm (Fig 1 A). 
In both transgenic and non-transgenic young and intermediate aged animals (age class I 
and II) very small amounts of ubiquitin-IR could be detected. Ubiquitin-1R was used as 
a marker for neurodegenerative processes. In the oldest SODI transgenic mice (age-
class III) intense ubiquitin-IR was present in spinal gray matter. Both intact cell bodies, 
in particular the motor neurons located in the anterior horn, as well as cell-related 
structures like dendrites and axons were ubiquitin-IR (not shown). 
The intrinsic anatomy of the adult mouse spinal cord was clearly demonstrated by 
the distribution of Py-IR, which was largely restricted to the gray matter (see also 
Houweling et al., 1999). More specific , the Py-IR was observed in the large motor 
neurons (located in the ventral hom lamina IX) (Fig.IB). The territory occupied by the 
Py-IR motor neurons was easily distinguished against the more weakly stained 
surrounding neuropil (Fig.IB). This intense filamentous Py-IR was localized in the cell 
bodies and the dendrites of the motor neurons; nuclei were unstained (Fig IB). 
Furthermore neurons in Rexed layers III to X , but also neurons in layer I were weak to 
moderate Py-immunoreactive (as reported by Houweling et al.[Houweling et al., 1999]). 
A clear difference in the pattern of ChAT/Py-immunofluorescent double staining 
could be noted between the oldest SODI mice (age-class III) and the age matched 
controls. The large motor neurons in the control animals showed bright ChAT/Py 
double staining and an intact cell membrane (Fig. 1B), whereas the motor neurons from 
the age-matched transgenic SODI-mice demonstrated a major loss of Py-staining, an 
irregular cell membrane and the presence of small inclusions in the perikarya (Fig 1D). 
In the youngest age-class (1) no microscopical differences in morphology between the 
motor neurons in transgenic versus non-transgenic was noted, whereas in the intermedi-
ate stage of disease (age-class group II) the transgenic mice were characterized by some 
early signs of degeneration, e.g the presence of vacuoles and some minor irregularities 
of the membranes of the motor neurons. 
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Figure 1. Immunocytochemical double-staining for Chat (A,C,E) and Py-IR (B,D,F). (A,B) Age-
matched control non-transgenic animal for disease stage III. Here numerous Chat-IR motor 
neurons in the anterior horn are characterized by their healthy appearance. Chat-IR motor 
neurons are also Py-IR. (C,D) Disease stage III SODI-(G93A) transgenic animal. A reduction of 
the relative Py-IR is present in the ChAT-IR motor neurons (arrows) indicating disease 
progression. (E,F) Disease stage III SODI-(G93A) transgenic animal. Only a few remaining 
Chat-IR motor neurons are present. These motor neurons are degenerating as they are 
charecterized by the irregularities of the cell membrane (arrows). Bar = 20 μηι. 
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Table 1. Quantification of the mean absolute and relative number of motor neurons during 
disease progression. 
Class Mean number of Mean relative number of 
motor neurons per section motor neurons per section (%) 
Control I 8.1 ±0.57 100.0 ±7.0 
SODl-(G93A)I 8.4 ±0.55 103.6 ±6.8 
Controlli 10.1 ±0.92 100.0 ±9.2 
S0D1-(G93A) II 8.2 ±0.71 81.0 ±7.0 
Control III 12.5 ±1.03 100.0±8.3 
SOD 1 -(G93A) III 7.5 ± 0.80 * 60.2 ± 6.4 * 
Data are expressed as mean ± SEM. Minimal number of sections used for analysis per group is 
30 *p<0 05 
Quantification of the number of motor neurons during disease progression. 
In the present investigation only those motor neurons were counted with visible 
nuclei. Due to the variation in the number of motor neurons between the various control 
(non-transgenic) groups, comparison of the absolute number of motor neurons per 
spinal cord section, between the age-classes, was not possible. For the absolute mean 
number of motor neurons per section see Table 1. Thus the relative number of motor 
neurons per section was used for each condition. First the mean number of motor 
neurons per section for the control group for each individual age-class was defined as 
100%. Subsequently, the mean relative number of motor neurons per spinal section of 
the transgenic SODI-mice as compared to the controls of same the age-class group was 
calculated. 
The relative number of ChAT-IR motor neurons per spinal cord section in the 
transgenic SODI mice of the oldest age-class group (III) was significantly decreased by 
39.8% as compared to the age-matched controls (Table 1; Fig 2). In the younger animals 
no (statistical) significant difference was observed between transgenic and age-matched 
non-trangenic animals (age-class I and II) (Table 1; Fig.2). 
Quantification of relative Py-staining intensity per motor neuron during disease 
progression. 
Variations in the background staining intensity did not allow comparison of the 
absolute Py-IR between age-classes. In order to correct for phenomena like cell swelling 
the Py-IR intensity was measured per μπι2 per ChAT-IR motor neuron. Therefore the 
relative Py-IR intensity per motor neuron (as a comparison between transgenic and non-
transgenic mice per age-class) was used in this study. 
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Figure 2. Quantification of the mean relative number of motor neurons per section in the lumbar 
spinal cord during disease progression. Disease stage 1: presymptomatic stage: disease stage II: 
intermediate stage: disease stage III: final stage of disease. * p< 0.05. 
Semi-automatic analysis of the mean relative Py-IR per spinal motor neuron of 
intermediate- and old-aged SODI transgenic mice (age-classes II and III) demonstrated 
a significant reduction as compared to the age-matched controls: in age-class II a 
reduction of 10.8% (controls 100 + 3.8; S0D1-(G93A) 89.2 + 3.6) and in age-class III a 
reduction of 13.3% (controls 100 + 3.7; SODl-(G93A) 86.7 + 5.0) (Fig.3). No signi­
ficant change in Py-IR between transgenic and non-transgenic mice of age-class I could 
be noted (controls 100 + 3.8; S0D1-(G93A) 98.7 + 3.8) (Fig.3). 
Discussion 
In the present study morphological signs of disease progression in the SOD(G93A) 
mice were noted: first, a significant decrease in the number of ChAT-IR motor neurons 
and second a general increase of ubiquitin-IR in the anterior horn of the lumbar spinal 
cord (see also refs [Dal Canto and Gumey, 1997; Gumey et al., 1994; Jaarsma et al., 
1996]). Based on quantitative analysis of immunocytochemical staining intensities (per 
μηι2 /ChAT-IR motor neuron and thus corrected for cell swelling), it is concluded that 
the relative Py-IR of spinal motor neurons is significantly decreased in the transgenic 
SODI-mouse as compared to age-matched controls during aging. 
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Figure 3. Quantification of the mean relative Py-IR intensity per (Chat-IR) motor neuron in the 
lumbar spinal cord during disease progression. *p< 0.05 
Interestingly this decrease in Py-IR per motor neuron is already observed before onset 
of massive motor neuron degeneration. 
The monoclonal antibody Py was initially developed as a tool for the identification 
of subpopulations of hippocampal neurons following microtansplantation [Field et al., 
1991; Fonseca et al., 1992; Woodhams et al., 1989]. Based on immuno-
electronmicroscopical studies it is suggested that the antigen recognized by Py is 
associated with the cytoskeleton [Brook et al., 1997a]. Furthermore, a rapid and marked 
sensitivity of the antigen recognized by Py was observed after axotomy as for instance 
illustrated by a rapid and profound reduction of Py-IR in Clarke's Nucleus neurons in 
the adult rat spinal cord after injury [Brook et al., 1997a]. Although the antigen recog­
nized by Py is yet to be fully characterized, its differential distribution in the CNS 
[Houweling et al., 1999; Woodhams et al., 1989] and its rapid and long-lasting loss after 
axotomy (which preceeds the loss of cytoskeletal MAP2-IR [Brook et al., 1997b]) 
suggests that the antibody is a useful tool in studying novel and early alterations in the 
cytoskeleton of identified cell populations. Our observations on the rapid loss of Py-IR 
in the motor neurons of S0D1(G93A) transgenic mice indicates that early filamentous 
alterations in the cytoskeleton of these neurons are involved in the pathological process 
during selective motor neuron death. Nevertheless, the question remains whether this 
Py-response is specific for neurodegeneration of motor neurons and not merely a result 
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of non-specific alterations in the cell body. The fact that previous studies have shown 
that Py-staining is reduced by axotomy [Brook et al., 1997b; Brook et al., 1998] 
supports the latter non-specific hypothesis. Since upper motor neurons do not 
degenerate in this mouse mutant, future experiments focussed on cortical motor neurons 
are planned in order to determine whether the reduction in Py-IR is specific for the 
neurodegenerative changes of the spinal motor neurons as observed in this transgenic 
mouse model. 
Cytoskeletal alterations have been suggested to play an important role in motor 
neuron diseases like ALS. Histo-pathological observations in human ALS revealed the 
presence of spheroids, consisting of 10 nm neurofilament-accumulations located in the 
axons of the spinal motor neurons [Carpenter, 1968]. Also the over-expression of the 
wild type human NF-Η or wild type NF-L gene has been shown to lead to impaired 
neurofilament transport folowed by axonal swellings, loss of kinetic activity, muscle 
atrophy and motor neuron degeneration [Collard et al., 1995; Cote et al., 1993; Xu et al., 
1993]. Furthermore variant alleles of the NF-Η subunit gene have been found in some 
human ALS patients, that all showed neurofilamentous accumulations in cell bodies and 
proximal axons [Vechio et al., 1996]. 
In the transgenic S0D1-(G93A) mouse model, neurofilamentous inclusions in the 
spinal motor neurons appeared together with vacuolation just before onset of clinical 
symptoms of the disease [Tu et al., 1996]. Immunocytochemical studies have shown the 
localization of ubiquitin on filamentous inclusions in the spinal cord of ALS patients 
[Migheli et al., 1990]. These results suggests that cytoskeletal elements are substrates of 
the ubiquitin degradation pathway. In the S0D1-(G93A) mouse ubiquitin-IR was 
observed in neuronal hyaline inclusions in the spinal cord during the advanced stages 
(age class III) of the motor neuron-disease [Shibata et al., 1998]. In our experiments 
ubiquitin-IR was included in order to verify the neurodegenerative process of the spinal 
motor neurons in our SODl-(G93A) transgenic mice. Indeed, both a changed morpholo­
gical appearance as well as an increased ubiquitination were observed during the course 
of the disease. These changes were, however, mainly resticted to the final stages of the 
disease (age-class III). The latter observations and the decreased Py-IR in the motor 
neurons of pre-symptomatic SOD 1 -(G93A) mice indicate that the antibody recognized 
by Py is of use for detection of cytoskeletal changes in de spinal motor neurons of the 
SODI transgenic mice. Unfortunately, the functional significance of the observed 
reduction of Py-IR in the spinal motor neurons of the S0D1-(G93A) mouse has yet to 
be determined. The presence of the Py-antigen in the adult spinal cord motor neurons 
and its early down-regulation may become important in the understanding of selective 
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vulnerability of motor neurons in SODl-(G93A) mice and in human ALS. Further 
studies are now underway to elucidate the full molecular structure of the Py-antigen, 
which then may shed light on these issues. 
Acknowledgements: 
We thank Peter Sodaar for development of the soft-ware for measuring Py-IR on the 
Quantimet-Leica system. This research was supported by grants from the EC, Biomed-
II # BMH4-96-1154 and the Spinal Cord Society Nederland. 
97 
Chapter 5 
References 
Anand,P., ParTett,A., Martin,J., Zeman.S., Foley,?., Swash,M., Leigh.P.N., Cedarbaum.J.M., 
Lindsay,R.M., Williams-Chestnut,R.E., and . (1995). Regional changes of ciliary 
neurotrophic factor and nerve growth factor levels in post mortem spinal cord and cerebral 
cortex from patients with motor disease. Nat. Med. /, 168-172. 
Bisby,M.A. and Tetzlaff,W. (1992). Changes in cytoskelelal protein synthesis following axon 
injury and during axon regeneration. Mol. Neurobiol. 6, 107-123. 
Brook,G.A., Nacimiento,W., Taheri,A.S., Woodhams,P.L., and Noth.J. (1997b). Axotomy-
induced alterations in the red nucleus revealed by monoclonal antibody, Py, following a low 
thoracic spinal cord lesion in the adult rat. Spinal Cord. 35, 474-481. 
Brook,G.A., Spitzer,C., Nacimiento.W., Kouchtir-Devanne,N., Woodhams,P.L., and Noth,J. 
(1997a). Differential distribution of immunoreactivity in the adult rat spinal cord revealed by 
the monoclonal antibody, Py: a light and electron microscopic study. Exp. Neurol. 146, 265-
276. 
Brook,G.A., Spitzer,C., Nacimiento,W., Woodhams,P.L., and Noth,J. (1998). A novel early 
component of the cell body response in axotomized Clarke's nucleus neurons revealed by 
monoclonal antibody Py. Exp. Neurol. 149, 64-72. 
Bruijn,L.l., Becher,M.W , Lee,M.K., Anderson,K.L., Jenkins,N.A., Copeland,N.G., Sisodia,S.S., 
Rothstein,J.D., Borchelt.D.R., Price,D.L., and Cleveland,D.W (1997). ALS-linked SODI 
mutant G85R mediates damage to astrocytes and promotes rapidly progressive disease with 
SOD 1-containing inclusions. Neuron 18, 327-338. 
Calvert,R.A., Woodhams,P.L., and Anderton.B.H. (1987). Localization of an epitope of a 
microtubule-associated protein 1 χ in outgrowing axons of the developing rat central nervous 
system. Neuroscience 23, 131-141. 
Carpenter,S. (1968) Proximal axonal enlargement in motor neuron disease. Neurology 18, 841-
851. 
Collard,J.F., Cote,F., and Julien,J.P. (1995). Defective axonal transport in a transgenic mouse 
model of amyotrophic lateral sclerosis. Nature 575, 61-64. 
Cotc,F., Collard,J.F., and Julien,J.P. (1993). Progressive neuronopathy in transgenic mice 
expressing the human neurofilament heavy gene: a mouse model of amyotrophic lateral 
sclerosis. Cell 73, 35-46. 
Dal Canto.M.C. and Gumcy.M E. (1997). A low expressor line of transgenic mice carrying a 
mutant human Cu,Zn superoxide dismutase (SODI) gene develops pathological changes that 
most closely resemble those in human amyotrophic lateral sclerosis. Acta Neuropathol (Beri) 
93, 537-550. 
Field.P.M., Scclcy,P.J., Frotschcr,M., and Raisman,G. (1991). Selective innervation of embryonic 
hippocampal transplants by adult host dentate granule cell axons Neuroscience 41, 713-727. 
98 
Cellular changes in motoneurons as revealed by monoclonal antibody Py 
Fonseca,M., Woodhams,P.L., Webb,M., Field.P.M., and Raisman,G. (1992). Monoclonal 
antibodies to late-differentiating epitopes identify mossy fibre terminals innervating normal 
and transplanted hippocampal CA3 pyramidal cells. Eur. J. Neurosci. 4, 448-458. 
Gumey.M.E., Pu,H·, Chiu,A-Y·, Dal Canto.M.C, Polchow.C.Y., Alexander,D.D., Caliendo,J., 
Mentati,Α., Kwon,Y.W., and Deng,H.X. (1994). Motor neuron degeneration in mice that 
express a human Cu,Zn superoxide dismutase mutation. Science 264, 1772-1775. 
Houweling,D.A., Brook.G.A., Gieling,R.G., Veldman,H., Woodhams,P.L., Nacimiento,W., 
NothJ., Bar,P.R., and Joosten,E.A. (1999). Differential distribution of immunoreactivity in 
the developing rat spinal cord revealed by the monoclonal antibody Py. Brain Res. Dev. Brain 
Res. 116,87-96. 
Jaarsma,D., Holstege,J.C., Troost,D., Davis,M., Kennis,J., Haasdijk,E.D., and de Jong,V.J. 
(1996). Induction of c-Jun immunoreactivity in spinal cord and brainstem neurons in a 
transgenic mouse model for amyotrophic lateral sclerosis. Neurosci. Lett. 219, 179-182. 
Kato,T., Hirano,A., and Kurland,L.T. (1987). Asymmetric involvement of the spinal cord 
involving both large and small anterior horn cells in a case of familial amyotrophic lateral 
sclerosis. Clin. Neuropathol. 6, 67-70. 
Martin,L.J. (1999). Neuronal death in amyotrophic lateral sclerosis is apoptosis: possible 
contribution of a programmed cell death mechanism. J. Neuropathol. Exp. Neurol. 58, 459-
471. 
Mighcli,A., Autilio-Gambetti,L., Gambetti,?., Mocellini,C., Vigliani,M.C., and Schiffer,D. 
(1990). Ubiquitinated filamentous inclusions in spinal cord of patients with motor neuron 
disease. Neurosci. Lett. 114, 5-10. 
Munoz,D G , Greene,C., Perl,D.P., and Selkoe,D.J. (1988). Accumulation of phosphorylated 
neurofilaments in anterior hom motoneurons of amyotrophic lateral sclerosis patients. J 
Neuropathol. Exp. Neurol. 47, 9-18. 
Rosen,D.R., Siddique,T., Pattcrson,D., Figlewicz,D.A., Sapp,P., Hentati,A., Donaldson,D., 
Goto,J., 0'Regan,J.P., and Deng.H.X. (1993). Mutations in Cu/Zn superoxide dismutase gene 
are associated with familial amyotrophic lateral sclerosis. Nature 362, 59-62. 
Shibata,N., Hirano,A., Kobayashi,M., Dal Canlo,M.C., Gumey,M.E., Komori.T., Umahara.T., 
and Asayama,K. (1998). Presence of Cu/Zn superoxide dismutase (SOD) immunoreactivity in 
neuronal hyaline inclusions in spinal cords from mice carrying a transgene for Gly93Ala 
mutant human Cu/Zn SOD. Acta Neuropathol. (Beri) 95, 136-142. 
Tu,P.H , Raju,P., Robinson,K.A., Gumey,M.E., Trojanowski,J.Q., and Lee,V.M. (1996). 
Transgenic mice carrying a human mutant superoxide dismutase transgene develop neuronal 
cytoskeletal pathology resembling human amyotrophic lateral sclerosis lesions. Proc. Natl. 
Acad. Sci U. S A 93, 3155-3160. 
Van Westerlaak,M G , Bar,P.R., Cools,A R., and Joosten.E.A. (2001) Malonate-induced cortico-
motoncuron death is attenuated by NT-4, but not by BDNF or NT-3. Neuroreport 12, 1355-
1358. 
99 
Chapter 5 
Vechio,J.D., Bruijn,L.I., Xu,Z., Brown,R.H., Jr., and Cleveland,D.W. (1996). Sequence variants 
in human neurofilament proteins: absence of linkage to familial amyotrophic lateral sclerosis. 
Ann. Neurol. 40, 603-610. 
Woodhams.P.L., Webb.M., Atkinson.D.J., and Seeley.P.J. (1989). A monoclonal antibody, Py, 
distinguishes different classes of hippocampal neurons. J. Neurosci. 9, 2170-2181. 
Xu.Z., Cork.L.C, GriffinJ.W., and Cleveland,D.W. (1993). Increased expression of 
neurofilament subunit NF-L produces morphological alterations that resemble the pathology 
of human motor neuron disease. Cell 73, 23-33 
100 
Chapter 6 
Summary and discussion 
101 
102 
Summary and discussion 
6.1 Summary 
In this thesis three major parts can be distinguished First, the development of a long 
term in vitro model of cortical slices in which cortical motor neurons (CMNs) can be 
identified and quantified (ch 2) Second, the induction of chronic toxicity on CMNs, 
which results in a cascade of toxic events as observed in neurodegenerative diseases 
such as amyotrophic lateral sclerosis (ALS) In this chronic m vitro model the 
underlying mechanism inducing CMN death was analyzed and compared with the 
underlying mechanism inducing spinal motor neuron death in a chronic m vitro model 
(ch 2,3,4) Furthermore, the neuroprotective effect of neurotrophins BDNF, NT-3, and 
NT-4 was studied (ch 4) Third, the use of the Py-antibody was investigated to 
determine early cellular alterations in motor neurons of the SODI transgenic mouse 
(ch 5) Py-immunoreactivity and cellular alterations were studied in spinal motor 
neurons, because no clear evidence of cortical motor neuron death in SODI transgenic 
mice is reported 
In chapter 1 the theoretical background of this thesis is given The pathogenesis of 
the neurodegenerative disease ALS and factors that are possibly involved in the 
neurodegenerative process by switching on the cascade of neurotoxic events are 
described Furthermore, factors that probably contribute to the selective vulnerability of 
affected motor neurons are listed 
In chapter 2 the development of a model in which cortical motor neuron (CMN) 
degeneration can be studied is presented In a long-term organotypic culture model of 
cortical slices CMNs were identified by a combination of SMI-32 immunoreactivity, 
their location in the expiant, their size, and their morphological appearance With 
chronic malonate treatment energy depletion was induced, resulting in a dose-dependent 
decrease of the number of CMNs in the expiants Both the NMDA-antagonist MK-801 
and the non-NMDA antagonist CNQX can neuroprotect the CMNs, suggesting that the 
malonate-induced mitochondrial inhibition results in glutamate toxicity via both NMDA 
and non-NMDA receptors 
In chapter 3 the selective vulnerability of the subgroup of CMNs that are affected in 
ALS is determined in an organotypic culture model Therefore, the vulnerability to 
energy depletion of CMNs in the dorsal part, where the corticospinal neurons he, is 
compared with that of CMNs in the ventral part We observed that the dorsally located 
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CMNs, thus including the corticospinal neurons, were less vulnerable to a 2-week 
period of mitochondrial inhibition with malonate as compared to ventrally located 
CMNs. Chronic treatment with 5 mM malonate resulted in 50 % CMN death in the 
dorsal part and 84 % in the ventral part. The mechanism by which the CMNs die differs 
between the dorsally located and the ventrally located CMNs: CNQX, MK801, and 
riluzole were neuroprotective for the dorsal CMNs, whereas only MK.-801 was 
neuroprotective for the ventral CMNs. These findings suggest that during the malonate-
induced cell death of dorsal CMNs both NMDA and non-NMDA receptors are 
involved, whereas in the cell death of ventral CMNs only occurs via NMDA receptors. 
In chapter 4 the neurotrophic effect of BDNF, NT-3, and NT-4 on the cell death of 
CMNs in an organotypic culture model after chronic mitochondrial inhibition with 
malonate was studied. 
Our data showed that treatment with various doses of NT-4 was neuroprotective for the 
CMNs resulting in a bell-shaped curve of the number of CMNs. NT-4 (10 ng) even 
completely prevented malonate toxicity in the dorsal and the ventral half of the expiant. 
Both BDNF and NT-3 had no neuroprotective effect at all. 
In chapter 5 the use of the Py antibody as an early marker for motor neuron 
degeneration in the S0D1-(G93A) mouse, an animal model for ALS, is discussed. Py 
determines early cellular changes. We also studied ubiquitin-immunoreactivity (IR), 
that is present in neuronal hyaline inclusions during the advanced stages of the motor 
neuron disease, to verify the progress of neurodegenerative processes in the spinal cord. 
Whereas an increase in ubiquitin-IR was not observed until the final stages, a decrease 
in Py immunoreactivity was already observed in spinal motor neurons in pre-
symptomatic stages of the disease in our S0D1-(G93A) mice prior to motor neuron 
death. This makes Py a possible early marker for spinal motor neuron degeneration. 
104 
Summary and discussion 
6.2 Discussion 
Based on the initial aims of this thesis, this discussion adresses four issues The first 
part (section 6 2 1) focusses on the development of a long term in vitro model in which 
cortical motor neurons (CMNs) are visualized and quantified in order to study chronic 
toxic processes The second part of the discussion (section 6 2 2) is built around the 
induction of chronic toxicity in this model through malonate-induced cell death of 
cortical motor neurons and the mechanisms involved In the third part (section 6 2 3), 
the effect of neurotrophic factors on CMN survival in this long-term culture model is 
discussed The fourth part of the discussion (section 6 2 4) focusses on the use of Py to 
determine early cytoskeletal changes in motor neurons Finally, the discussion ends 
(section 6 3) with suggestions for fiiture directions of ALS research based on the 
findings described in this thesis 
6.2.1 An in vitro approach to study CMNs within the cortical 
expiant and to study CMN death in relation to chronic treatment 
strategies 
Both spinal and cortical motor neurons are affected m ALS, but in experimental 
studies most attention so far has been focussed on the spinal motor neurons [Camu and 
Henderson, 1992, Kaal et al, 1997, Rothstein et al , 1993, Rothstein and Kuncl, 1995] 
Very little is known about the selective cell death of cortical motor neurons in ALS In 
order to study the cell death of cortical motor neurons in vitro, we set up a culture 
system that closely resembles the in vivo situation with respect to the number and 
developmental stage of CMNs Because the degeneration of motor neurons in ALS is a 
chronic process, the study had to be carried out in a long-term culture system 
Therefore, we set up an organotypic slice culture model of rat cortical tissue cultured on 
a membrane (see also [de Jong and Ruijter, 1989, Kaal et al, 2000, Rothstein et al, 
1993, Stoppini et al , 1991] ) which allowed a long-term preservation of the expiants 
[de Jong and Ruijter, 1989, Stoppini et al , 1991] Indeed, we observed a close 
resemblance between ongoing developmental processes in our rat cortical expiants in 
vitro as compared to the in vivo development (see also[de Jong and Ruijter, 1989, Ha et 
al, 1998, Nicolai, 1981]) Nissl-staining after 1, 2, and 4 weeks in culture showed the 
appearance of clearly identifiable cortical layers It is therefore concluded that this 
model is suitable for long-term (chronic) treatment studies 
To study the survival of the layer V pyramidal cells within the cortical expiant, 
CMNs had to be visualized for correct identification and quantification As there is no 
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specific immunocytochemical marker for selective visualization of CMNs, optimal 
identification of CMNs can be achieved by retrograde tracing of these cells. However, 
although the application of the fluorescent retrograde tracer Fluoro-Red into the spinal 
cord of one-day-old rat pups [Dong et al., 1996] results in selectively labelled CMNs in 
the cortex (fig.l and [Dijkstra et al., 1999]), we found that after the first week in culture 
most of the label is diffusely distributed throughout the expiant. Surrounding glial cells 
probably take up the tracer from labeled dying CMNs [Rinaman et al., 1991]. Therefore, 
we concluded that retrograde tracing cannot be used for correct identification and 
quantification of CMNs in long-term cultured expiants. 
As an alternative, we identified CMNs by staining them immunohistochemically 
with SMI-32, an antibody against non-phosphorylated neurofilament. SMI-32 is present 
in the CMNs in large amounts. Indeed, the location of SMI-32 positive cells after the 
Figure 1. Fluoro-Red retrogradely labels CMNs when injected in the cervical spinal cord of a 1-
day-old rat (PI) (survival time 20 h) or a 6-day-old rat (P6) (survival time 20 h). a. Freezing 
microtome section of 40 fM of the frontal cortex afa 2-day-old rat (Fluoro-Red injection at PI). 
b. Section of the frontal cortex of a 7-day-old rat (Fluoro-Red injection at P6). 
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first week in culture was comparable to the location of retrogradely labeled CMNs in 
the cortex of a 4-day-old rat in vivo [Schreyer and Jones, 1988]. Furthermore, a double 
staining procedure, using Fluoro-Red tracing and SMI-32 immunocytochemistry, 
showed co-localization in large pyramidal cells located in layer V of the cortex 4 weeks 
after culturing (fig.2). Although CMNs are SMI-32 immunoreactive, they are not 
exclusively stained. In contrast with the in vivo situation in 4-week-old rats, where only 
pyramidal cells in layers III and V of the cortex could be visualized with SMI-32 [Ha et 
al., 1998], we also observed immunopositive stellate cells in layers II, 111, IV and VI in 
a cortical expiant after 4 weeks in culture. Because layer V projection neurons are 
already in their correct somatotopical location at postnatal day 1 [Hicks and D'Amato, 
1968], we included their position in the expiant, their morphological appearance, and 
their size for correct identification of CMNs in the cortical expiants. 
Figure 2. Double staining with Fluoro-Red (injection at PI) and SMI-32 in long-term cultured 
slices (4 weeks). Occasionally, a double-stained cell can be detected. Bar = 20jU m. a. Fluoro-Red 
is visible in a CMN (arrow) and is further distributed throughout the slice, b. SMI-32 staining of 
the same Fluoro-Red labelled CMN as shown in a (arrow). 
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For chronic treatment studies, a more or less constant number of CMNs in the 
expiants is a prerequisite After quantification of the SMI-32 positive CMNs in time 
during the first 4 weeks in culture, we found that from 2 weeks in vitro onwards the 
cultures were suitable to study the effect of chronic treatment on the survival of CMNs 
Whereas in vivo CMN death is small to negligible [Finlay and Slattery, 1983], in 
organotypic slice cultures there is some additional cell death between the first and the 
second week in culture This is probably the result of dissection damage at the edges of 
the expiant After the second week in vitro a steady state in the number of cortical cells 
is reached The same pattern for the total number of cortical cells in organotypic slice 
cultures has been observed by De Jong and Ruijter [de Jong and Ruijter, 1989] 
6.2.2 Chronic mitochondrial inhibition by malonate induces cell 
death of cortical motor neurons in an organotypic culture model 
It is well known that a cascade of neurotoxic events can underlie neuronal death m 
stroke or neurodegenerative diseases Among these events, mitochondrial dysfunction, 
glutamate toxicity, calcium toxicity, formation of reactive oxygen species (ROS), and 
cytoskeletal changes play a prominent role All these factors may play a primary or 
secondary role in the cascade of neurotoxic events as observed during pathogenesis of 
ALS It is generally accepted that excitotoxicity plays an important role in this cascade 
An excess of glutamate causes over-stimulation of glutamate receptors resulting in an 
uncontrolled calcium influx [Beai, 1995] [Novelli et al, 1988] Mitochondrial 
dysfunction, resulting in energy depletion [Beai et al, 1993], may lead to secondary 
excitotoxicity [McLaughlin et al, 1998] and can in this way initiate the cascade leading 
to the cell death of motor neurons in ALS (see ch 1 2 1) To mimic the pathological 
processes as seen in ALS in a long-term culture, it is possible to induce (secondary) 
excitotoxicity in motor neurons by chronic glutamate transport inhibition with DL-
threo-ß-hydroxyaspartate (THA) [Rothstein et al, 1993] or by chronic mitochondrial 
inhibition with complex II inhibitor malonate [Kaal et al , 2000] Although THA was 
succesfully used to induce slow neurotoxicity in organotypic spinal cord cultures 
[Rothstein et al, 1993], it could not be used in our cortical culture model The induced 
toxicity to cortical motor neurons by THA appeared to have a steep dose respons curve, 
resulting in low reproducibility of cell death Based on these findings it was concluded 
not to use the THA-neurotoxicity model for further studies (unpublished results of De 
Vrij and Van Westerlaak, lab Exp Neurol Utrecht) 
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Malonate dose-dependently induces motor neuron death in organotypic cultures of 
rat spinal cord [Kaal et al , 2000] Also in our cortical expiants, chronic mitochondrial 
inhibition resulted in a dose-dependent increase of CMN death in the slices (ch 2) 
Therefore, we concluded that malonate can be used to mimic chronic toxic processes for 
motor neurons in spinal cord as well as cortical slices 
What mechanisms are involved in the malonate-induced motor neuron death ? 
Energy depletion due to chronic mitochondrial inhibition with malonate results in 
secondary excitotoxicity [Beai et al, 1993] The malonate-mediated glutamate 
excitotoxicity can occur via NMDA and occasionally via non-NMDA receptors, that are 
both present on upper and lower motor neurons [Beai et al, 1993, Estevez et al, 1995] 
In motor neurons of spinal cord slices (secondary) excitotoxicity induced by malonate 
or THA is mediated through non-NMDA receptors [Kaal et al, 2000, Rothstein et al, 
1993] and not through NMDA receptors [Kaal et al, 2000] In contrast, we showed that 
malonate-induced cell death of cortical motor neurons in organotypically cultured slices 
can be decreased by the NMDA antagonist MK-801 and the non-NMDA antagonist 
CNQX, which suggests that both NMDA and non-NMDA receptors are involved (ch 2) 
Differences in calcium permeability of the glutamate receptors and receptor density may 
underlie the observed differences in glutamate receptor involvement in spinal and 
cortical motor neuron death 
The involvement of the NMDA receptor in motor neuron death can be deduced from 
the fact that the density of NMDA receptors is higher on motor neurons that are affected 
in ALS and in the deep layers of the cortex as compared to unaffected motor neurons 
[Shaw et al , 1994a] Nevertheless, malonate-induced cell death of spinal motor neurons 
in organotypic cultures does not occur via NMDA receptors [Kaal et al, 2000] 
Differences in subunit composition may underlay this discrepancy In rat spinal motor 
neurons both the NR2d and NR3a subunit are expressed, together with the NR1 and 
NR2a-c subumts [Abdrachmanova et al, 2000], resulting in a decreased calcium 
permeability [Goebel and Poosch, 1999] 
The density of non-NMDA receptors is decreased on motor neurons that are affected 
in ALS [Chinnery et al, 1993], suggesting that non-NMDA receptors are not involved 
in the pathogenesis of ALS However, in expenmental models for ALS, cell death of 
spinal motor neurons occurs via non-NMDA AMPA receptors [Kaal et al , 2000] A 
possible explanation for this phenomenon is that a subgroup of AMPA receptors on 
spinal motor neurons lack the GluR2 subunit [Williams et al, 1997] and is therefore, 
unlike other AMPA receptors, permeable for calcium [Greig et al, 2000] Furthermore, 
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the number of AMPA receptors is increased in the spinal cord of ALS patients, 
suggesting an increasing vulnerability during the course of the disease [Shaw et al., 
1994b]. GluR2 has been detected on all pyramidal layer V cells (CMNs) in all cortical 
areas in rat [Conti et al., 1994b; Conti et al., 1994a], resulting in calcium-impermeable 
AMPA receptors [Geiger et al., 1995; Martin et al., 1993; Vissavajjhala et al., 1996]. 
Nevertheless, the neuroprotective effect of CNQX on the CMNs in our studies suggest 
that possibly also a subgroup of non-NMDA AMPA receptors on CMNs lack the 
GluR2 subunit. Besides differences between receptors in vivo, the involvement of the 
AMPA receptors in the spinal motor neuron death in organotypic cultures and the CMN 
death in our cultures may also be explained by down-regulation of the GluR2 subunit 
after axotomy [Tang and Sim, 1997]. In our cortical expiants the outgrowing 
corticospinal tract axons that have reached cervical and thoracic levels in the spinal cord 
at postnatal day 1 are axotomized during the dissection procedure [Gribnau et al., 1986; 
Stanfield and O'Leary, 1985]. 
Does mitochondrial inhibition induce selective motor neuron death? 
After succesfully developing a long-term culture system in which cell death of 
CMNs could be studied, the question arose whether the mechanisms by which malonate 
induces cell death of affected spinal motor neurons and corticospinal neurons are 
comparable, and whether energy depletion inhibition selectively affects these motor 
neurons. As mentioned before (ch.l, table 1), the most striking differences between 
affected and non-affected motor neurons are found in the glutamate receptor density, 
and the density and velocity of glutamate transporters. Remarkably, in the malonate-
induced cell death of both the affected spinal motor neurons [Rothstein et al., 1993] and 
dorsal CMNs non-NMDA receptors play a role, whereas in the cell death of the ventral 
CMNs they do not. This suggests that the selective degeneration of motor neurons as 
observed in ALS occurs via non-NMDA receptors that differ from non-NMDA 
receptors on unaffected neurons. As mentioned before differences in subunit 
composition (GluR2 presence/ absence) may underlay this difference [Greig et al., 
2000; Henderson et al., 1993; Tang and Sim, 1997]. In addition to the non-NMDA 
involvement, NMDA receptors also play a role in the cell death of dorsal CMNs in our 
model. Nevertheless, NMDA receptor involvement is not exclusive for dorsal CMNs, as 
cell death of ventral CMNs also occurs via NMDA receptors. 
In spinal cord organotypic slice cultures, mitochondrial inhibition resulted in 
selective motor neuron death; more cell death of motor neurons was observed as 
compared to calretinin-IR intemeurons [Kaal et al., 2000]. In our model we compared 
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the cell death of dorsally located CMNs, including corticospinal neurons that are 
affected in ALS, with those located in ventral parts of the cortex. Unexpectedly, the 
ventrally located CMNs appeared to be more vulnerable. A higher density of NMDA 
receptors on ventral CMNs as compared to the dorsal CMNs may underlay this higher 
vulnerability. Furthermore, the results may be influenced by the culturing procedure. 
Axotomy of afferent and efferent connections of the cortical tissue affect the receptor 
subunit composition. Finally, the plasticity of dorsal CMNs may be higher than the 
plasticity of ventral CMNs, because corticospinal neurons have not yet reached their 
target area at postnatal day 1, whereas ventral CMNs have already established synaptic 
connectivity in vivo prior to dissection [Gribnau et al., 1986; Joosten et al., 1987]. From 
this observation we concluded that it is possible to distinguish various CMN 
populations within a cortical expiant which allows the comparison of various CMN 
populations within one expiant. Nevertheless, the relevance of this model for human 
ALS, with the lower vulnerability of affected dorsal CMNs, might be less prominent. 
6.2.3 Can neurotrophins protect cortical motor neurons against 
malonate-induced cell-death in the organotypic culture model ? 
Because neurotrophins play an important role during development and during 
regeneration after injury [Giehl and Tetzlaff, 1996; Oppenheim, 1996], and low 
concentrations of the neurotrophins brain-derived neurotrophic factor (BDNF), 
neurotrophin -3 (NT-3) and neurotrophin-4 (NT-4) increase survival of isolated spinal 
motor neurons in culture [Henderson et al., 1993; Hughes et al., 1993; Kaal et al., 
1997], we hypothesized that neurotrophins may increase the survival of cortical motor 
neurons in our organotypic slice cultures after chronic mitochondrial inhibition [Novelli 
et al., 1988]. Furthermore, observations in ALS patients suggest a role for neurotrophins 
in the pathogenesis and progression of the disease. The TrkB receptor, the receptor for 
BDNF and NT-4, is much less phosphorylated in ALS resulting in disturbed 
intracellular signalling [Mutoh et al., 2000]. TrkB expression in the spinal cord is 
increased in ALS [Meyer et al., 1992]. Furthermore, BDNF and ΝΤ-3-like 
immunoreactivity is decreased in motor neurons in post mortem sections of the spinal 
cord of ALS patients [Duberley et al., 1997; Nishio et al., 1998] and the normally absent 
nerve growth factor (NGF)- and TrkA-like immunoreactivity are increased in ALS, 
suggesting a switch in neurotrophin dependence [Nishio et al., 1998]. In our 
organotypic culture model we observed that NT-4, but not BDNF or NT-3, completely 
prevented malonate-induced CMN death in both the dorsal and the ventral part of the 
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cortical explant (eh 4, Van Westerlaak et al, 2001a) The same results were obtained 
with spinal motor neurons in an organotypic culture model with glutamate transport 
inhibition [Corse et al , 1999] and in (short-term) primary cultures of rat cortical motor 
neurons [Corse et al, 1999, Junger and Varon, 1997] NT-3 and BDNF can protect 
against calcium- and free radical-mediated toxicity following mitochondrial inhibition 
[Mattson et al, 1993] BDNF can affect the subunit composition of NMDA receptors 
and non-NMDA AMPA receptors resulting in a changed calcium permeability [Brene et 
al, 2000, Glazner and Mattson, 2000], and NT-3 and BDNF can reduce possible 
calcium overload by increasing the intracellular calcium-binding molecule D28k 
calbindin [Collazo et al , 1992, Mattson et al , 1993] In contrast, the mechanism by 
which NT-4 protects motor neurons remains unclear Non-NMDA receptors are known 
to be involved in the THA-induced cell death of spinal motor neurons and malonate-
induced cell death of spinal motor neurons [Corse et al , 1999, Kaal et al, 2000] We 
found that NMDA-receptors are involved in malonate-induced CMN death of both 
dorsal and ventral CMNs (ch 3,Van Westerlaak et al , 2001b) Based on these 
observations, we suggest that NT-4, like BDNF [Glazner and Mattson, 2000], may also 
have a direct effect on non-NMDA and NMDA receptors, by changing their subunit 
composition or by changing the density of the receptors Furthermore, NT-4 may, in 
accordance to BDNF and NT-3, increase the intracellular expression of calcium-binding 
molecule D28k 
Remarkably, BDNF and NT-4 exert their effect via the same receptor but only NT-4 
increases the survival of CMNs in our expiants This differential effect may be related 
to a direct or indirect action of BDNF and NT-4 on the survival of spinal and cortical 
motor neurons [Junger and Junger, 1998] The effect of NT-4 on corticospinal cells 
mainly occurs indirectly through astroglial cells [Junger and Junger, 1998], that are also 
present in our cortical expiants, whereas the effect of BDNF on isolated spinal motor 
neurons occurs in the absence of glial cells [Henderson et al, 1993, Hughes et al, 1993, 
Kaal et al, 1997] The existence of two different Trk-B receptors on glial and neuronal 
cells, the truncated gpl45trkB and the full-length gp95trkB receptor respectively, may 
contribute to the differential effect of NT-4 and BDNF [Roback et al, 1995] The 
presence of truncated Trk-B receptors reduces the response of the full-length Trk-B 
receptors [Al Chalabi et al, 1998] Nevertheless, because NT-4 and BDNF both bind to 
truncated ass well as full-length TrkB receptors, the precise mechanism underlying the 
observed differential effect remains unclear In conclusion, NT-4 but not BDNF and 
NT-3 are neuroprotective for motor neurons in a spinal culture model for ALS, as well 
as in our cortical culture model [Corse et al, 1999], suggesting that NT-4, and not 
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BDNF or NT-3, may be a good candidate to prevent cortical as well as spinal motor 
neuron loss in ALS 
6.2.4 Is Py suitable as early marker for motor neuron death in 
SODI transgenic mice? 
In a parallel study, we focussed on the early detection of degeneration of motor 
neurons in vivo In a first attempt, we used the degeneration of the spinal motor neurons 
in the S0D1-(G93A) transgenic mouse, an animal model for ALS In SODI mice, 
motor neurons in the spinal cord, but not in the cortex, degenerate Among the earliest 
events in ALS are neurofilament-accumulations and abnormal assembly of the 
neurofilament structures in the motor neurons [Hirano, 1991] In the transgenic SOD1-
(G93A) mouse model, neurofilament aberrations appear in the spinal motor neurons 
before clinical onset of the disease [Tu et al, 1996] Although it is not sure that 
neurofilament aberrations are a primary cause of motor neuron disease, neurofilaments 
are thought to be important risk factors for ALS, because their concentration is high in 
motor neurons and they are vulnerable to oxidative stress [Chou et al, 1996, Manetto et 
al, 1988] and glutamate toxicity [Miller et al, 2000] (see eh 1 2 1 and 1 2 2 5) 
In S0D1-(G93A) mice, ubiquitin-IR has been observed in neuronal hyaline 
inclusions in the spinal cord during the advanced stages of the disease [Shibata et al , 
1998] We observed a changed morphological appearance and increased ubiquitination 
during the final stages of the disease with ubiquitin-IR (ch 5) 
Py-immunoreactivity, suggested to be associated with the neurofilamentous and 
microtubular elements of the cytoskeleton of spinal motor neurons [Woodhams et al, 
1989], is one of the first indicators of cytoskeletal changes in the cell body and is even 
more sensitive than MAP-2, a previously used early indicator of cytoskeletal alterations 
[Brook et al, 1998] It was therefore suggested that the Py antigen may be a sensitive 
tool for detection of early alterations of the cytoskeleton in affected motor neurons 
With the Py antibody we found a significant decrease in Py-IR in the pre-symptomatic 
stages of the disease even before the onset of massive motor neuron degeneration The 
reduction of Py-IR in the spinal motor neurons of pre-symptomatic SODl-(G93A) mice 
indicates that the antibody recognized by Py can be used for early detection of cellular 
changes The Py-reduction is probably even more prominent than reported, because 
during quantification those cells with undetectable amounts of Py-IR were excluded 
The number of these cells was significant higher in the symptomatic stages of the G93A 
mice than in the controls Nevertheless, the functional significance of the decreased Py-
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IR in the spinal motor neurons of the SOD-1-mouse remains unclear and there is so far 
no information about the Py-IR in cortical motor neurons in ALS or animal models for 
ALS. 
6.3 ALS-research, what lies ahead? 
Switching on the cascade of neurotoxic events as observed in ALS by malonate-
induced mitochondrial inhibition can be used in in vitro models for motor neuron death 
(ch.2 and 3). Although malonate induces cell death of both the affected spinal motor 
neurons and dorsal CMNs via non-NMDA receptors, dorsal CMN death also occurs 
through NMDA receptors. If the apparent differences between affected motor neuron 
populations in vitro are also present in ALS patients, treatment of ALS will require a 
more complex therapy. In future in vitro studies, the somatotopical location and 
presence of the glutamate-receptor subtypes and subunits need to be investigated to 
elucidate the findings in this thesis. 
In clinical trials for ALS, BDNF has been shown to have no beneficial effect. 
Whereas NT-3 and BDNF had no neuroprotective effect on cortical motor neurons nor 
on spinal motor neurons in an organotypic culture model, NT-4 was neuroprotective for 
spinal as well as cortical motor neurons in organotypic cultures. From these results we 
conclude that NT-4 may be a better candidate to prevent motor neuron death in ALS as 
tested in clicinal trials. 
Cellular and cytoskeletal changes are observed very early in ALS, suggesting an 
important role in the pathogenesis. These intracellular changes are even thought to play 
a primary role in ALS. The Py antigen can be used to detect very early cellular changes 
in spinal motor neurons. The use of Py as a marker for cortical motor neuron 
degeneration needs to be further investigated. Unfortunately, no good in vivo model for 
cortical motor neuron death is yet available. Therefore, the development of a good in 
vivo model for degeneration of cortical motor neurons would be a large step forward in 
the study of mechanisms involved in motor neuron death in ALS and the search for 
therapeutic strategies. 
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Het onderzoek dat in dit proefschrift beschreven is gericht op de neurodegeneratieve 
ziekte amyotrofische lateraal sclerose (ALS) Bij deze ziekte degenereren motor 
neuronen in cortex, hersenstam en ruggenmerg, wat resulteert in spasticiteit en 
verlamming ALS manifesteert zich meestal pas rond de leeftijd van 55 jaar en resulteert 
in het algemeen in een overlijden 2 tot 3 jaar na het stellen van de diagnose Binnen de 
groep van ALS patieenten zijn twee vormen te onderscheiden een erfelijke vorm (10%) 
en een sporadische vorm (90%) Binnen de groep met een erfelijke vorm is bij 10-20% 
(dus 1-2 % van de totale groep) een mutatie gevonden in het gen dat codeert voor 
koper/zink superoxide dismutase (SODI), een enzym dat belangrijk is voor de 
verdediging van cellen tegen superoxide radicalen Omdat de oorzaak van ALS nog 
grotendeels onbekend is is er nog geen adequate behandeling voor de celdood in ALS 
voorhanden Het is wel bekend dat de celdood van de motor neuronen waarschijnlijk 
wordt veroorzaakt door een cascade van schadelijke reacties Bij ALS patiënten zijn 
gevonden morfologisch veranderde mitochondria, defekten in de elektronen transport 
keten van mitochondria, gezwollen Endoplasmatisch Reticulum, verhoogde glutamaat 
concentraties in plasma en cerebrospinale vloeistof , een verminderde heropname van 
glutamaat door omliggende cellen, antistoffen tegen calcium-kanalen, neurofilament 
accumulaties in motor neuronen en, zoals hierboven genoemd, mutaties in het SOD1-
gen Aan de hand van deze informatie wordt aangenomen dat mitochondnele 
dysfiinctie, glutamaat toxiciteit, een te hoog intracellulair calcium gehalte, oxide 
radicalen en veranderingen in het cytoskelet een belangrijke rol spelen bij het afsterven 
van de motor neuron Omdat al deze factoren zowel primair kunnen zijn alswel 
secundair aan een van de andere factoren is het moeilijk te bepalen welke factor of 
welke factoren bij ALS de cascade in gang zetten en welke het gevolg ervan zijn 
Binnen het onderzoek naar ALS wordt over het algemeen gekeken naar de celdood 
van spinale motor neuronen In dit proefschrift ligt het accent voornamelijk bij de 
corticale motor neuronen Het onderzoek is m drie onderdelen te onderscheiden Ten 
eerste de ontwikkeling van een lange termijn in vitro model van corticale plakken, 
waarin corticale motor neuronen (CMNs) kunnen worden geïdentificeerd en 
gekwantificeerd (hoofdstuk 2) Ten tweede, het induceren van chronische toxiciteit 
binnen het model, wat resulteert in een cascade van schadelijke reacties zoals die gezien 
wordt bij degeneratieve ziektes zoals ALS In dit chronische in vitro model werden de 
mechanismen geanalyseerd die leidden tot CMN dood en vergeleken met de 
123 
Samenvatting 
mechanismen die betrokken waren bij spinale motor neuron dood in een chronisch in 
vitro model (hoofdstuk 2,3,4) Verder werd het neuroprotectieve effect van 
neurotrofines BDNF, NT-3 en NT-4 bestudeerd (hoofdstuk 4) Ten derde, het 
bestuderen van het gebruik van het Py-antihchaam om vroege cellulaire verandenngen 
in motor neuronen van S0D1-(G93A) transgene muizen te vinden (hoofdstuk 5) SODI 
transgene muizen vormen het enige adekwate in vivo model voor ALS De 
aanwezigheid van Py immunoreactiviteit en cellulaire veranderingen werden bekeken in 
spinale motor neuronen omdat er geen bewijs is voor corticale motor neuron dood in 
S0D1-(G93A) transgene muizen 
In hoofdstuk 1 wordt de theoretische achtergrond gegeven van dit proefschrift De 
Pathogenese van ALS en mogelijk betrokken factoren binnen het neurodegeneratieve 
proces van de motor neuronen worden beschreven Verder worden factoren die mogelijk 
bijdragen tot de selectieve gevoeligheid van aangedane versus met-aangedane motor 
neuron-populaties geïnventariseerd 
In hoofdstuk 2 wordt de ontwikkeling van een model waarin corticale motor neuron 
(CMN) degeneratie kan worden bestudeerd gepresenteerd In een lange-termijn 
organotypisch kweek model van corticale plakken werden CMNs geïdentificeerd door 
een combinatie van SMI-32 immunoreactiviteit, de locatie binnen de plak, de celgrootte 
en de morfologische kenmerken Door middel van chronische behandeling met de 
mitochondnele remmer malonaat werd energie depletie geïnduceerd, hetgeen 
resulteerde in een dosis-afhankelijke afname van het aantal CMNs in de plak NMDA-
antagomst MK-801 en non-NMDA antagonist CNQX beschermden gingen beide de 
dood van de CNfNs tegen Dit suggereert dat de mitochondnele inhibitie door malonaat 
leidt tot glutamaat toxiciteit via NMDA receptors en via non-NMDA receptors 
In hoofdstuk 3 wordt de selectieve gevoeligheid van CMNs die aangedaan zijn in 
ALS bepaald in een organotypisch kweek model Hiertoe werd de gevoeligheid van 
dorsaal gelocahseerde CMNs, inclusief corticospinale neuronen die aangedaan zijn in 
ALS, vergeleken met ventraal gelocahseerde CMNs Het bleek dat de dorsale CMNs 
minder gevoelig waren voor mitochondnele inhibitie met malonaat gedurende twee 
weken dan de ventrale CMNs Behandeling met 5 mM malonaat resulteerde in 50 % 
sterfte van dorsale CMNs en 84 % sterfte van ventrale CMNs De mechanismen die bij 
de celdood betrokken zijn verschillen tussen de dorsale en de ventrale CMNs CNQX, 
MK-801 en nluzole verhoogden de overleving van dorsale CMNs maar alleen MK-801 
beschermde de ventrale CMNs Hieruit kan worden geconcludeerd dat bij de malonaat-
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geïnduceerde celdood van de dorsale CMNs zowel NMDA als non-NMDA receptoren 
betrokken zijn, maar bij de celdood van de ventrale CMNs alleen NMDA receptoren. 
In hoofdstuk 4 werd het neuroprotectieve effect van BDNF, NT-3 en NT-4 op de 
celdood van CMNs in een organotypisch kweek model na chronische mitochondriële 
inhibitie bestudeerd. In onze experimenten bleek dat behandeling met verschillende 
doses NT-4 resulteerde in een verhoogde overleving van de CMNs. NT-4 (10 ng) 
voorkwam zelfs CMN dood door malonaat volledig in het dorsale alswel in het ventrale 
gedeelte van de plak. BDNF en NT-3 hadden beide geen neuroprotectief effect. 
In hoofdstuk 5 wordt het gebruik van het Py-antilichaam als een vroege marker voor 
motor neuron degeneratie in de S0D1-(G93A) muis, een diermodel voor ALS, bekeken. 
Py bepaalt vroege cellulaire veranderingen. Daarnaast hebben we naar ubiquitine-
immunoreactiviteit gekeken, wat gezien wordt in insluitsels in het ruggenmerg tijdens 
latere stadia van de motor neuron ziekte, om het neurodegeneratieve proces te 
verifiëren. Ubiquitine-immunoreactiviteit werd pas in de eindstadia gezien, terwijl een 
afname van Py-immunoreactiviteit al zichtbaar was in presymptomatische stadia van de 
ziekte in onze SOD 1 muizen voordat er werkelijk motor neuron dood optrad. 
In hoofdstuk 6 worden de resultaten uit de voorgaande hoofdstukken (2 - 5) 
samengevat en bediscussieerd. De belangrijkste conclusies met betrekking tot de 
bevindingen: 
- Er zijn mogelijk verschillende mechanismen betrokken zijn bij de celdood van spinale 
en corticale motor neuronen, waardoor behandeling, gericht op beide motor neuronen, 
complexer zou kunnen zijn. Om verder uitsluitsel te krijgen over de betrokken 
glutamaat receptors moeten de verschillende bij motor neuron dood betrokken receptors 
worden gelocaliseerd en hun 'subunit' samenstelling in verschillende hersengebieden en 
ruggenmerg worden geanalyseerd. 
- Er is in clinical trials gebruik gemaakt van BDNF, maar gezien onze resultaten en de 
resultaten van anderen in een model voor spinale motor neuron dood lijkt NT-4 een 
betere kandidaat. 
- Het Py antilichaam kan gebruikt worden om vroege cellulaire veranderingen aan te 
tonen in spinale motor neuronen. Helaas is nog niet duidelijk of deze marker ook te 
gebruiken is voor de celdood van corticale motoneuronen, omdat hiervoor nog geen 
goed in vivo model bestaat. 
Om de celdood van corticale motor neuronen te kunnen bestuderen zou een in vivo 
model moeten worden ontwikkeld met selectieve degeneratie van corticale motor 
neuronen. 
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Abbreviations 
AD 
ALS 
AMPA 
ATP 
BDNF 
BSA 
ChAT 
CMNs 
CNQX 
CNS 
CS 
EAAT 
ER 
fALS 
FITC 
GBSS 
HBSS 
HD 
i.p. 
MAP 
MAPK 
MEM 
MK-801 
MPP+ 
NAIP 
NF 
NGF 
NGS 
NMDA 
NOS 
NT-3 
Alzheimer's disease 
amyotrophic lateral sclerosis 
a-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid 
adenosine triphosphate 
brain-derived neurotrophic factor 
bovine serum albumine 
choline-acetyl-transferase 
cortical motoneurons 
6-cyano-7-nitroquinoxaline-2,3-dione 
central nervous system 
corticospinal 
excitatory amino acid transporter 
endoplasmic reticulum 
familial ALS 
fluorescein isothiocyanate 
Gey's balanced salt solution 
Hank's Balanced Salt Solution 
Huntington's disease 
intra peritoneal 
microtubule associated protein 
mitogen-activated protein kinase 
minimal essential medium 
(+)-5-methyl-10,1 l-dihydro-5//-dibenzo[a,i/]cyclohepten-5,1 Ο­
Ι -methy 1-4-phenylpyridinium 
neuronal apoptosis inhibitory protein 
neurofilament 
nerve growth factor 
normal goat serum 
N-methyl-D-aspartic acid 
nitric oxide synthase 
neurotrophin-3 
imine 
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NT-4 
PB 
PBS 
PCR 
PD 
PND 
ROS 
sALS 
SEM 
SMN gene 
SODI 
THA 
Trk 
neurotrophin-4 
phosphate buffer 
phosphate buffered saline 
polymerase chain reaction 
Parkinson's disease 
postnatal day 
reactive oxygen species 
sporadic ALS 
standard error of the mean 
survival motor neuron gene 
copper/zinc superoxide dismutase 
DL-threo-ß-hydroxyaspartate 
tyrosine-kinase 
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De route naar dit proefschrift is uiteindelijk anders gebleken dan bij aanvang 
verwacht Na een weg vol kuilen, een lange vertraging, een omleiding en nog twee 
kleinere vertragingen is nu dan toch het eindpunt bereikt Omdat bij het doen van 
promotie-onderzoek en het schnjven van een proefschrift een heleboel mensen 
betrokken zijn, wil ik graag een aantal mensen bedanken voor hun bijdrage 
Nijmegen (aio-penode deel 1) 
Ten eerste Yessie Gnbnau die mij in Nijmegen de mogelijkheid bood onderzoek te 
doen naar de ontwikkeling van de corticospinale baan Hoewel wij heel goed en fijn 
samen konden werken en ik nog heel veel van jou kon leren hebben externe factoren 
ertoe geleid dat ik mijn aio-penode helaas niet bij jou heb kunnen afronden 
Jos Dederen, als analist onmisbaar bij de afdeling anatomie en embryologie Ik heb 
het als heel prettig ervaren met jou te mogen werken, dankzij jouw kennis en 
enthousiasme heb ik 2 jaar een luxe-leventje geleid als aio Gelukkig hebben we elkaar 
na de Nijmeegse periode met uit het oog verloren, ik hoop dat de toekomst er voor jou 
rooskleurig uitziet' 
Helmy Mulders, mede-aio van het eerste uur Samen met jou, drank, drop en 
chocolade was het goed toeven in het Nijmeegse Toen JIJ, inmiddels gepromoveerd, 
Nijmegen veruilde voor Perth werd het gelijk een stuk stiller op onze kamer (en op de 
hele afdeling)' 
Alle andere (ex) medewerkers van de afd Anatomie en Embryologie Het lijkt al 
weer heel lang geleden dat ik rondliep op het lab in Nijmegen Dankzij jullie 
aanwezigheid heb ik ook in Nijmegen een leuke tijd gehad 
Utrecht (aio-penode deel 2) 
Dop Bar, promotor, dank voor de geboden mogelijkheid om mijn onderzoek voort te 
zetten in jouw lab Experimentele Neurologie in het UMC te Utrecht Dankzij jouw 
plaats dicht bij het lab en dicht bij de aio's heb ik ervaren dat een promotor niet altijd 
iemand is die ver van de promovendus af staat Jouw enthousiasme en betrokkenheid bij 
mijn onderzoek hebben zeker bijgedragen aan het halen van de eindstreep 
Lex Cools, ook promotor maar dan uit Nijmegen, wij kenden elkaar al lang voordat 
ik in Utrecht verzeild raakte Omdat JIJ graag nauw betrokken wilde zijn bij het wel en 
wee van het onderzoek en de artikelen is de afstand Nijmegen - Utrecht niet zo heel 
groot gebleken Zeker via de electronische snelweg kunnen artikelen je snel bereiken, 
zelfs in Japan Bedankt voor al je moeite en tijd 
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Dankwoord 
Bert Joosten, co-promotor, zonder jou was dit boekje er waarschijnlijk nooit 
gekomen Omdat JIJ geloofde in de mogelijkheid te promoveren binnen afzienbare tijd, 
met aanpassing van het onderwerp, ben ik in Utrecht terecht gekomen Jouw inzet en de 
vele versies artikelen die je (snel) hebt willen lezen zal ik niet snel vergeten Ik hoop dat 
je het in Maastricht, in je favoriete onderzoeksgebied, nog ver zult schoppen en ik hoop 
voor aio's en studenten daar dat ze jou als begeleider mogen knjgen 
Alle leden van het Aio (later LAJO)-overleg, gelukkig blijkt het overleg eens in de 
zoveel tijd onontbeerlijk en zijn de toelatingseisen in de tijd niet te hoog gebleken Evert 
Kaal, Dr Kaal, lange tijd hebben wij zij aan zij gestreden voor het ALS-onderzoek, 
tenminste als mijn bureau nog zichtbaar was onder jouw papierberg Sipke Dijkstra, 
Siepke, altijd kritisch op eigen werk maar ook op dat van anderen Evert en Sipke, 
zullen we nog eens een congresje plannen7 Het levert zulke mooie kiekjes op' Diane 
Houwelmg, gelukkig hebben we geen lab nodig om elkaar te zien Ildiko van Rhijn, 
eigenwijs is ook wijs' Veel succes in Amenka Jaap Jansen, meneertje peertje Japio, 
gelukkige kon je mijn flauwe 'plakseltjes' wel waarderen Leanne Saiker, Lejanneke, 
bedankt voor je gezellige aanwezigheid op het lab Liselijn Wisman, laatste aanwinst 
van het LAJO-gebeuren, JIJ hebt je een waardig lid getoond, dankzij jou houdt het 'Aio-
overleg' een vinger in het lab 
Henk Veldman en Peter Sodaar, dankzij jullie konden al mijn praktische problemen 
altijd wel opgelost worden Jullie stonden altijd voor me klaar Bedankt voor jullie 
inzet' 
'Mijn' studenten Femke de Vrij en Come Biesheuvel, jullie hebben voor mij bergen 
werk verzet Femke, helaas moest je aan den lijve ondervinden dat het doen van 
onderzoek niet altijd het gewenste resultaat oplevert Corne, nadat het kweekwerk was 
opgegeven na mysterieuze infecties in de kweken, heb je toch nog goed werk verricht 
met ruggenmerg van SODI-muizen waar een mooi artikel uit is gekomen 
Andere (ex) medewerkers en studenten op lab, bedankt voor de leuke tijd die ik met 
jullie heb mogen hebben op en buiten het lab 
Paranimfen, Evert en Diane, fijn dat jullie achter mij willen staan op de 'grote dag' 
Mijn ouders, mijn zussen, schoonfamilie, een goede achterban is onontbeerlijk Jullie 
zijn er altijd in blijven geloven, en ziehier het is inderdaad gelukt' 
Mijn mannen, Wiek, Tom en Cas, bedankt dat jullie er zijn' De promotie heeft door 
twee zwangerschappen wel wat langer geduurd, maar jullie hebben mijn leven nog 
leuker gemaakt' 
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Mariette van Westerlaak werd op 18 juni 1968 geboren te Nijmegen. In juni 1986 
behaalde zij haar diploma ongedeeld VWO aan het Elshofcollege te Nijmegen. In 
datzelfde jaar startte zij haar studie biologie aan de Katholieke Universiteit Nijmegen. 
Binnen deze studie koos zij voor de medische richting, waarin zij in november 1993 
afstudeerde. In 1989/1990 liep zij een bijvakstage bij de afdeling 
Psychoneurofarmacologie van de Faculteit der Medische Wetenschappen van de 
Katholieke Universiteit Nijmegen. Daar deed zij onder leiding van dr. Geke Ploeger en 
prof. dr. Lex Cools onderzoek naar de rol van de Nucleus Accumbens in de acquisitie 
van een plaats navigatie taak. Haar bijvakstage liep zij in 1991/1992 bij de afdeling 
Farmacologie van de Faculteit der Geneeskunde van de Vrije Universiteit te 
Amsterdam. Onder supervisie van prof. dr. S.E. Wendelaar Bonga deed zij onder 
leiding van dr. Freek van Muiswinkel en prof. dr. Harry Steinbusch onderzoek naar 
trofe factoren voor een mesencephale dopaminerge neuronenkweek. In april 1994 begon 
zij als assistant in opleiding bij de afdeling Anatomie en Embryologie van de Faculteit 
der Medische Wetenschappen van de Katholieke Universiteit Nijmegen, waar zij 
onderzoek deed naar de ontwikkeling, plasticiteit en regeneratie van corticospinale 
verbindingen bij de rat onder leiding van dr. Yessie Gribnau. Revalidatie na een zwaar 
auto-ongeluk op 6 juli 1994 leidde ertoe dat dit onderzoek voor eenjaar werd stilgelegd, 
waama het tot eind 1997 werd voortgezet. Daarna leidde een reorganisatie binnen de 
medische faculteit tot een detachering naar de afdeling Experimentele Neurologie van 
het Utrechts Medisch Centrum begin 1998. Hier werd het onderzoeks-ondenverp 
veranderd en in de twee volgende jaren verrichtte zij onder leiding van prof. dr. Dop 
Bär en dr. Bert Joosten onderzoek naar de celdood van corticale motor neuronen als een 
model voor Amyotrofische Lateraal Sclerose. Dit heeft geresulteerd in dit proefschrift. 
Tijdens de periode in Utrecht is zij getrouwd met Wiek Thijssen en moeder 
geworden van Tom en Cas. 
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Stellingen behorende bij het proefschrift 
Upper motor neuron death in ALS 
mechanistic studies in an in vitro model 
Het corticale motor neuron is het stiefkindje binnen het ALS onderzoek 
Corticale motor neuronen laten zich niet gemakkelijk vangen in een kleuring (dit 
proefschrift) 
Corticale en spinale motor neuronen kunnen binnen het ALS onderzoek niet als 
gelijke worden behandeld (dit proefschrift) 
Hoewel er diermodellen zijn met een op ALS gelijkende ziekte, is geen enkele 
'ALS-muis' echt bruikbaar zolang er geen sprake is van degeneratie van corticale 
motor neuron 
Gezien het positieve effect van NT-4 op de overleving van zowel spinale als 
corticale motor neuronen in vitro zou NT-4 een goede kandidaat kunnen zijn 
voor de preventie van spinale en corticale motor neuron degeneratie bij ALS. 
De corticospinale baan is van groot belang bij de dissectie van een kweek met 
corticospinale neuronen 
Het reizen van hoofdstukken van een proefschrift gaat het best via de 
electromsche snelweg, dit geeft weinig file en is niet onderhevig aan vertraging 
's-Hertogenbosch houdt het midden tussen Nijmegen en Utrecht 
Waarom genoegen nemen met één man als je er nog twee bij kunt krijgen 
Na pre-klinisch onderzoek volgt logischerwijs klinisch onderzoek 
Manette van Westerlaak, maart 2002 


